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 Prostate cancer (PCa) remains the most commonly diagnosed solid tumor and is 
the third leading cause of cancer-related death in United States men. While androgen 
deprivation therapy is the current standard-of-care treatment for metastatic PCa, most 
patients eventually relapse and develop castration-resistant (CR) tumors, for which there 
is currently no effective treatment. Therefore, synthesis of novel therapeutic agents and 
identification of alternative target proteins are necessary to improve treatment. Herein, I 
investigate the efficacy of novel imidazopyridine and statin derivatives as alternative 
therapeutic compounds. These molecules not only inhibit androgen receptor signaling, 
but also block activation of the AKT axis, a mechanism of androgen independence. 
Furthermore, I investigate the role of p66Shc, a 66 kDa Src and collagen homologue 
oxidase, in the mechanism of PCa metastatic progression. p66Shc is elevated in clinical 
PCa as well as multiple PCa cell lines which correspond with advanced CR PCa. 
Additionally, p66Shc has been demonstrated to promote proliferation in PCa cell lines 
via generation of reactive oxygen species (ROS). This study is the first to demonstrate 
p66Shc also regulates PCa cell migration through ROS production and identifies key 
ROS-sensitive proteins pivotal to its mechanism. Understanding how p66Shc promotes 
migration may lead to the identification of alternative therapeutic targets for suppression 
of CR PCa metastatic activity. Overall, this study seeks to support future efforts to 
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1.1 Progression of Prostate Cancer and Castration-Resistance 
Prostate cancer (PCa) is the most commonly diagnosed carcinoma and third 
leading cause of cancer-related death in American men, with 161,360 new cases and 
26,730 deaths estimated in 2017 [1,2]. PCa mainly affects older men with the majority of 
PCa diagnosed in men over the age of 65 and the disease rarely observed in men 
younger than 40. On average, 1 in every 7 men will be diagnosed with PCa in the course 
of their lifetime and 1 in every 39 men will die from PCa [2,3]. While the causes of PCa 
initiation are still being studied, both genetic and environmental factors such as diet, 
smoking, and exercise, contribute to tumor development [4]. The development of PCa is 
thought to adhere to the “multi-hit” nature of carcinogenesis in which a number of 
mutational events eventually lead to tumor initiation and later malignant transformation 
[3,4]. Typically, PCa is a slow-growing cancer and, as with most solid tumors, localized 
PCa is generally not lethal and effectively treated by means of surgery or radiation 
therapy. In some instances, PCa patients may not require treatment if the disease is not 
expected to affect their normal life span [5,6]. It is not until the tumor becomes metastatic 
and begins to invade surrounding tissue that it is life threatening. Thus, the ability to 
distinguish indolent and lethal tumors is the subject of intense focus in the field of PCa 
research. 
The prostate is a glandular organ composed of lumen lined mainly with epithelial 
cells as well as the occasional neuroendocrine cell, all of which are anchored to a basal 
membrane [7-8]. Multiple lumen structures are held together by stromal tissue composed 
of fibroblasts, myoblasts, smooth muscle cells, and neurons in addition to vascular 
tissues [7]. Importantly, the vast majority of prostate tumors develop from prostate 
epithelial tissue, meaning they are adenocarcinoma. This distinction is critical because 
prostate epithelial cells express high levels of androgen receptor (AR) compared to other 
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prostate tissues, thus tumors of this origin are primarily regulated by androgens in terms 
of growth and development [9]. Therefore, metastatic PCa is initially treated with 
androgen deprivation therapy (ADT) in which the body undergoes physical or chemical 
castration [10]. However, as with the majority of hormone-dependent cancers, many 
PCa patients relapse into the “hormone-refractory” or “castration-resistant” (CR) form of 
the disease within a few years (Fig. 1.1) [11]. Despite the tumor’s lack of response to 
ADT, most CR PCa still maintains some reliance on androgen receptor signaling and 
androgens for the receptor’s activation [12]. Current therapeutic strategies for CR PCa 
revolve around AR inhibitors such as enzalutamide, abiraterone acetate, and Casodex. 
Chemotherapeutic agents like docetaxel, which targets the mitotic spindle complex and 
inhibits the cell division, are also used to slow the disease’s progression [13-14]. 
However, the most effective therapies for CR PCa are currently only able to extend 
patient survival by about 3 months, maintaining a need for more effective treatment 
options [14]. Thus, because the inhibition of androgen receptor has only marginal effect, 
new therapeutic targets must be identified. In addition, molecules involved in the process 
of CR PCa cell proliferation, survival, and migration have the potential to be promising 
new targets for metastatic PCa. Understanding what regulates PCa cell metastatic 
progression would allow for the development of new agents to better treat the disease 
and possibly prevent metastasis from initially occurring. More importantly, knowledge of 
how the CR phenotype specifically controls growth and migration will aid the 
development of novel treatment options for patients who have already progressed to 






1.2 Key Prostate Cancer Associated Proteins 
While many mutations may occur during the development of PCa, deregulation of 
several protein signaling pathways have been identified as playing a major role in 
development of castration resistance. The first of these is androgen receptor itself, but 
also included are proteins directly regulated by androgens, such as p66Shc, and their 
downstream signaling pathways. Additional proteins regulating cell growth, survival, 
migration, and overall metastatic progression are also of keen therapeutic interest and 
include ErbB-2, cPAcP, AKT, and ERK. 
1.2A AR and PSA 
 Human PCa primarily originates from prostate epithelial cells, thus it is 
characterized as adenocarcinoma and its growth is regulated by androgens [9]. In the 
male body, the pituitary gland releases luteinizing hormone which stimulates leydig cells 
in the testes to produce androgens [15]. These are then distributed throughout the body 
via the bloodstream in the form of testosterone [16]. Upon entering prostate epithelial 
cells, testosterone is converted to 5α-dihydrotestosterone (DHT) by 5α-reductase in the 
cytosol [17]. AR, which is normally bound by heatshock proteins (HSP) 27 and 90 in the 
cytosol, is released upon binding DHT, allowed to form dimers, and enter the nucleus 
where it acts as a transcription factor for multiple proteins essential to cell growth and 
survival [18]. In the absence of androgens, prostate epithelial cells undergo apoptosis, 
thus in the early stages of prostate cancer ADT is very effective at reducing tumor 
volume (Fig. 1.2) [19-20]. 
 Unfortunately, the majority of PCa patients eventually relapse after initial 
treatment and becomes hormone-refractory or castration-resistant, meaning the tumor 
cells are resistant to ADT or no longer require external androgens for growth and 
development [21]. There are a number of mechanisms through which tumors may obtain 
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the castration-resistant phenotype. First, while ADT significantly reduces circulating 
androgen levels, it does not completely abolish androgen production and instead lowers 
androgen concentrations to about a 10% their original level [22]. In some cases, PCa 
cells increase AR levels to compensate for lower levels of androgen, sensitizing the cells 
to even minute concentrations of testosterone [23]. In addition, there are reports that 
PCa cells can also obtain the complete steroidogenic ability to synthesize their own 
androgens, bypassing the need of external sources [24]. AR may also become mutated, 
allowing for receptor promiscuity or constitutive activation, bypassing the need for 
androgens altogether [25]. Furthermore, AR can be post-translationally modified via 
phosphorylation by kinases such as PKA, AKT, and MAPK, activating AR and inducing 
nuclear translocation [26-27]. Finally, activation of key downstream signaling targets of 
AR, such as ErbB-2, can circumvent the need for AR activation [28]. 
 One of the most pervasive methods for tracking PCa disease progression in 
patients is monitoring serum levels of prostate-specific antigen (PSA) [29]. PSA is a 
member of the kallikrein-peptidase family of enzymes whose function is proposed to 
liquefy semen in the seminal coagulum to allow sperm to swim freely [30-31]. Ordinarily, 
PSA is regulated by androgen receptor and produced by prostate epithelial cells for 
secretion into seminal fluid [32]. While PSA is found in high levels in prostate epithelium 
and seminal fluids, it has relatively very low expression in all other tissues, thus it is a 
potent biomarker used to measure overall androgen receptor activity in the body [33-36]. 
After undergoing androgen-ablation therapy, patient serum PSA levels drop dramatically 
to an undetectable level [35]. Physicians then continue to monitor patient serum PSA 
levels for an eventual increase, indicating the tumor has relapsed and acquired the 




1.2B p66Shc and Reactive Oxygen Species 
Recent studies have shown AR promotes PCa metastatic phenotype in part by 
increasing levels of cellular reactive oxygen species (ROS) [38]. In part, this is achieved 
via an AR-mediated increase in levels of p66Shc protein, a 66 kDa proto-oncogene Src 
and collagen homologue protein, that exhibits oxidase activity and is one of three 
members of the Shc family, including isoforms p52Shc and p46Shc (Fig. 1.3) [39-40]. All 
three Shc isoforms possess C-terminal Src homology 2 (SH2), collagen homology 1 
(CH1), and phosphotyrosine binding (PTB) domains (Fig. 1.4). While p52Shc and 
p46Shc are ubiquitously expressed, p66Shc expression is more tightly regulated due to 
the presence of an alternative promoter which endows p66Shc with additional 
cytochrome C-binding (CB) and N-terminal collagen homology 2 (CH2) domains and 
provide it with supplementary functions [41-45]. p66Shc also differs from the other Shc 
isoforms in that its protein level is up-regulated by androgens that play a critical role in 
the process of PCa progression [46]. This is achieved via AR-induced stabilization of 
p66Shc, preventing ubiquitin-mediated degradation and causing an increase in cellular 
levels [47]. Recently, p66Shc protein is shown to be elevated in clinical PCa tissue 
samples, higher than in adjacent non-cancerous cells, and its protein level correlates 
with metastatic potential of PCa cell lines, including the LNCaP cell progressive model 
[48-49]. Levels of p66Shc have also been found to correlate with acquisition of 
androgen-independence in a number of PCa cell line models. For example, LNCaP C-33 
cells are androgen-sensitive and possess relatively low levels of p66Shc protein [50]. In 
contrast, as C-33 cells progress to C-81 cells, they become unresponsive to androgen 
deprivation and exhibit many biochemical properties seen in clinical CR PCa: including 
functional AR expression, androgen-independent prostate-specific antigen (PSA) 
secretion, malignancy and proliferation with intracrine growth regulation [48,50-51]. The 
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LNCaP C-81 cells also possess elevated p66Shc protein level [50]. This data has been 
further verified using a similar MDA PCa2b cell progressive model in which p66Shc 
protein level correlates with acquisition of androgen-independence and enhanced 
metastatic phenotype [46]. Interestingly, AR-null, androgen-independent (AI) PC-3 and 
DU145 cells possess a much more aggressive metastatic phenotype than LNCaP and 
MDA PCa2b cells as well as comparatively higher levels of p66Shc [46,50]. This 
suggests p66Shc is regulated by mechanisms in addition to AR activation. 
The p66Shc protein can be regulated at both the transcriptional and post-
translational levels. At the transcriptional level, modifications made to the p66Shc 
promoter, such as DNA methylation or histone deacetylation, result in silencing of 
p66Shc while demethylation or deacetylase enzymes promote p66Shc transcription 
[41,52-59]. Moreover, several transcription factors, including Nrf2 and STAT4, are 
reported to bind to p66Shc-specific promoters and promote transcription [60-61]. Post-
translationally, p66Shc contains a number of phosphorylation sites which can modulate 
its activity or stability. These include sites shared by the other Shc adaptor proteins such 
as p38 phosphorylation of T386 in the CH1 domain which prevents ubiquitination and 
S138 phosphorylation by MEK1/PKC in the PTB domain which alters Shc protein 
activity, preventing it from binding Grb2 [61-64]. p66Shc also possess phosphorylation 
sites in its N-terminal CH2 domain, which are not shared with p52Shc and p46Shc. 
These include S54 phosphorylation by p38 preventing ubiquitination and S36 
phosphorylation by ERK/JNK that induces cytosol to mitochondria translocation in 
response to stress stimuli [65-67]. 
In epithelial cells, p66Shc is localized in both the cytosol and mitochondria [68]. 
Upon mitochondrial translocation, p66Shc binds and oxidizes cytochrome C, uncoupling 
the electron transport chain and promoting generation of ROS [44]. ROS are natural by-
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products of cellular respiration and contribute to essential signaling pathways; however, 
when produced in excess, they also readily oxidize proteins, lipids, and nucleic acids, 
which facilitate cancer development [69-70]. Moreover, ROS are also known to regulate 
metastatic processes, including proliferation and migration, which are critical to cancer 
metastasis [71-72]. 
In addition, p66Shc has been shown to promote phosphorylation and activation 
of ErbB-2 (HER2) at Y1221/2 and Y1248 by promoting oxidation and subsequent 
inactivation of cellular prostatic acid phosphatase activity (cPAcP), an authentic protein 
tyrosine phosphatase and negative regulator of ErbB-2 [75-77]. Downstream targets of 
ErbB-2, including AKT and ERK, are also shown to be activated by p66Shc [76-77]. 
These proteins promote cell survival, proliferation, and migration and play a pivotal role 
in p66Shc’s ability to enhance the metastatic potential of CR PCa [75,78-79]. 
1.2C ErbB-2 and cPAcP 
Protein-tyrosine kinases (PTKs) are a large multigene family in humans. These 
PTKs are involved in key cellular processes regulating differentiation, cellular 
development, and multicellular communication by transferring a phosphate group from 
ATP to the hydroxyl group of tyrosine [80]. Moreover, perturbation of PTK signaling 
results in the development of numerous disease conditions, including cancer [80]. A 
thorough study of this family of proteins over the past two decades has demonstrated 
that about ninety genes have been identified in the human genome, along with five 
pseudogenes [81-82]. Among the 90 identified tyrosine kinases, fifty-eight encode for 
receptor tyrosine kinases (RTKs) that are further divided into 20 subfamilies. The 
remaining 32 genes are classified as non-receptor tyrosine kinases and further classified 
into 10 subfamilies [82]. 
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Results of previous studies suggest that the activation of receptor tyrosine kinase 
signaling is one of the major mechanisms through which PCa cells promote metastatic 
phenotype through the activation of subsequent effector pathways such as 
phosphoinositide 3-kinase (PI3K), protein-kinase B (PKB or AKT) and, mitogen-activated 
protein kinase (MAPK) and [83]. The human EGF receptor family consists of four distinct 
RTKs ErbB1-4, each possessing a number of synonymous gene names: 
EGFR/HER1/ErbB-1, NEU/HER2/ErbB-2, HER3/ ErbB-3 and HER4/ErbB-4. All 
members of the ErbB family of protein tyrosine kinases possess an extracellular domain, 
hydrophobic transmembrane section, juxtamembrane segment, an intracellular domain 
with kinase activity, and a cytoplasmic tail containing potential tyrosine phosphorylation 
sites [84]. The extracellular portion is further divided into four domains: these include 
domains I and III which are leucine-rich and responsible for ligand binding, while 
domains II and IV are cysteine-rich and facilitate dimerization via disulfide bonds. RTKs 
that exist as monomers are considered to be inactive [85-86]. Following the extracellular 
domain is a single-pass transmembrane segment consisting of 19-25 hydrophobic 
residues, a 40-residue juxtamembrane portion which plays a role in dimerization, a 
protein kinase domain, and a carboxyterminal tail [86]. Interestingly, extracellular 
domains I and II of ErbB-2 have no ligand-binding function, thus ErbB-2 monomer is 
potentially inactive [87]. Instead, ErbB-2 relies on heterodimerization with other ErbB 
family members for ligand-induced activation. Moreover, the protein kinase domain of 
ErbB-3 in kinase-impaired, thus ErbB-2 and ErbB-3 homodimers are potentially inactive 
[85,87]. 
Structurally, ErbB-2 maintains a naturally open conformation in which the 
dimerization arm of domain II is exposed. This is achieved through the substitution of a 
glycine residue with proline in domain II as well as a histidine residue with phenylalanine 
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in domain IV, preventing domain II and IV association in ErbB-2 [88].  While the wild-type 
ErbB-2 does not normally form homodimers, if the dimerization domain is in the open 
conformation homodimerization may occur [89]. While other ErbB family members are 
autoinhibited via a buried dimerization arm, constitutive activation of ErbB-2 is normally 
prevented by eight disulfide bonds in domain II that are partially disrupted upon 
heterodimerization with activated ErbB-1/3/4 [90]. Interestingly, it has been shown that in 
cancer cells overexpressing wild-type ErbB-2, the receptor homodimerizes and self-
activates due to the large number of molecules present [91]. However, overexpression of 
ErbB-2 is rare in PCa. More often, ErbB-2 is reported to be hyper-activated through 
elevated levels of phosphorylation [50,76]. 
While ErbB-2 is not directly activated by ligands, indirect activation is achieved 
via heterodimerization to other ligand-bound ErbB family members. Moreover, ErbB-2 is 
the preferred heterodimeric partner for other ErbB receptors [92-93]. Several studies 
suggest that overexpression/mutation/loss of ErbB-2 results in deregulation of 
dimerization and the downstream signaling of other ErbB family members [94]. In 
addition, heterodimers containing ErbB-2 induce elevated ligand binding affinity of the 
partner receptor [95]. The ErbB-2 receptor heterodimerization results in the 
phosphorylation of specific tyrosine residues in the receptor cytoplasmic tails and 
subsequent increase in kinase enzymatic activity and phosphorylation of several 
intracellular targets [96]. 
Upon heterodimerization, ErbB-2’s cytoplasmic kinase domains are 
phosphorylated, leading to protein kinase activation. Therefore, the phosphatases that 
can reverse ErbB-2 phosphorylation are capable of inhibiting its signaling cascade. 
Cellular prostatic acid phosphatase (cPAcP) is a dual specificity prostate-specific 
phosphatase that can dephosphorylate tyrosine, serine, and threonine residues with a 
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preference for p-Tyr [97-99]. In human prostate cells, ErbB-2 has been identified as a 
target of cPAcP by co-immunoprecipitation experiments that demonstrate the interaction 
between the two proteins and dephosphorylation of its tyrosyl residues (50,76,99). The 
loss of cPAcP has also been shown to be an early event in PCa and therefore is likely a 
prominent cause of ErbB-2 hyper-activation commonly observed in PCa [100]. For 
example, as androgen-sensitive LNCaP and MDA PCa2b cell lines progress to the 
androgen-independent castration-resistant phenotype, their levels of ErbB-2 
phosphorylation increase while cPAcP levels decrease [75-77,83,97]. Additionally, 
cPAcP knock-down in androgen-sensitive LNCaP cells results in enhanced ErbB-2 
phosphorylation and androgen-independent cell proliferation [76,97]. Similarly, cDNA 
transfection of cPAcP-deficient androgen-independent LNCaP or cPAcP-null PC-3 cells 
results in a decrease of ErbB-2 phosphorylation as well as the reacquisition of the 
androgen-dependent growth phenotype [76]. Importantly, prostate adenocarcinoma 
archival specimens show decreased cPAcP expression at both an mRNA and protein 
levels, further supporting a general trend of decreased cPAcP activity and enhanced 
ErbB-2 activation with PCa progression [76]. 
1.2D AKT and ERK 
Deregulation of protein kinase B (PKB), commonly referred to as “AKT”, is 
pervasive in PCa progression due to the protein’s regulation of mechanisms critical to 
metastasis [101]. The AKT signaling pathway promotes cell survival, proliferation, 
migration, invasion and other biological events associated with carcinogenesis [102-104. 
Further, AKT activation via T308 or S473 phosphorylation is primarily controlled by the 
phosphoinositide 3-kinase (PI3K)/ phosphatase and tensin homolog (PTEN) axis [105-
106]. Once activated by RTKs such as ErbB-2, PI3K converts phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) which activates a 
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number of downstream signaling components, the most notable of which is AKT [107]. 
Conversely, PTEN catalyzes the opposite reaction, converting PIP3 back into PIP2 and 
preventing activation of AKT [108]. Indeed, deregulation of this signaling network is very 
common in PCa with genetic loss and/or mutations in the PI3K/AKT pathway present in 
up-to 42% of primary prostate tumors and over 90% of metastatic tumors. Loss of tumor-
suppressor PTEN function is also considered one of the driving events of PCa 
development; homozygous and heterozygous PTEN deletions are frequently observed in 
localized PCa and to an even higher degree in aggressive metastatic tumors [109-111]. 
Interestingly, cPAcP can also hydrolyze PIP3, and in PTEN-inactive, cPAcP-deficient 
LNCaP C-81 cells, AKT is hyper-activated by phosphorylation, higher than that in 
LNCaP C-33 cells that express higher cPAcP. It is thus proposed that cPAcP is a PTEN-
functional homologue in prostate epithelia; as such, cPAcP is involved in the early stage 
of PCa development, while PTEN plays a major role in advanced carcinogenesis [75]. 
Upon activation, AKT regulates a number of cellular processes critical to PCa 
progression. For example, AKT promotes cell survival by inactivating pro-apoptotic 
proteins such as p53, BAX, BAD, YAP, and Caspase-9, while inducing anti-apoptotic 
proteins such as Bcl-2, BcL-XL, and Survivin [112-114]. AKT also stimulates cell 
proliferation by enabling the cell to overcome cell cycle arrest at the G1 and G2 phases 
through activation of Cyclin D1, CDKA, and CDK6 as well as activating other pro-growth 
signaling molecules such as mTOR [115]. Additionally, AKT promotes angiogenesis 
though VEGF activation as well as cell migration and invasion though regulation of 
cadherin proteins, MYC, matrix metalloproteinases, Snail, and FOXM1 [116-119]. AKT 
also stimulates cholesterol synthesis, which can be used by some advanced prostate 
tumors for de novo androgen synthesis [120]. Thus, AKT is capable of promoting the 
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aggressive metastatic phenotype in PCa and has the potential to be a useful therapeutic 
target. 
In PCa, AKT and AR share an overlapping complex signaling network in which 
each is capable of regulating the other. Through activation of p66Shc, AR promotes an 
increase in cellular ROS levels that leads to the inactivation of phosphatases such as 
cPAcP through oxidation of their active domains [77]. By preventing cPAcP inhibition of 
ErbB-2, AR promotes activation of a number of ErbB-2-regulated pathways. Among 
these signaling pathways is the activation of the PI3K/AKT pathway [77]. Similarly, AKT 
can modulate the transcriptional activity of AR through direct phosphorylation. For 
example, phosphorylation of AR at S210 and S790 by AKT suppresses AR-mediated 
apoptosis and contributes to PCa survivability [121]. Further, AKT can bind and 
phosphorylate AR at S213, increasing AR ligand-binding and promoting AR activation 
and translocation to the nucleus [122]. Moreover, in the event of AR inhibition or 
androgen-deprivation, the PI3K/AKT pathway is reported to become increasingly 
activated in PCa cells as a mechanism of androgen-independence, Thus AKT is has the 
potential to be a useful therapeutic target for CR PCa treatment [122-123]. 
In addition to AKT, activated ErbB-2 induces the mitogen-activated protein kinase 
pathway (MAPK), which includes extracellular signal-regulated kinases (ERK) proteins 
[124,125]. These proteins are frequently reported to be aberrantly activated in PCa and 
are key regulatory kinases for processes vital to PCa development and progression 
[50,77,126]. At the cell membrane, activated RTKs initially recruit GRB2 and SOS 
proteins that facilitate GDP-GTP nucleotide exchange of the RAS protein [127]. RAS 
then goes on to activate the RAF and then MEK, which finally activates ERK1/2 via T202 
and Y204 phosphorylation [127,128]. ERK is a serine-threonine kinase and its isoforms 
are classified into ERK1 and ERK2 groups according to their coding sequences [129]. 
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Once activated ERK regulates several processed critical to PCa progression such as 
survival, proliferation, migration via activation of transcription factors such as Elk1 [130-
132]. Similar to AKT, ERK and AR signaling pathways undergo cross-talk and feed-back 
loops [133-134]. Through ErbB-2 regulation, AR is able to promote downstream 
activation of ERK [133]. In turn, ERK can influence AR through induction of the CREB1 
transcription factor that binds AR promoter and enhances its transcription [135]. ERK is 
also capable of direct phosphorylation of AR and its coregulators, increasing AR activity 
and promoting its translocation to the nucleus [133,135,136]. Thus, like AKT, ERK is 
potential therapeutic target for future CR PCa treatment due to its promotion of 
metastatic phenotype as well as induction of AR signaling. 
1.3 Conclusions and Transition 
While androgen-sensitive PCa is effectively treated by ADT, therapeutic options 
for CR PCa remain limited with no adequate treatment available. Moreover, most current 
treatment strategies for CR PCa continue to focus AR inhibition. Therefore, new 
therapeutic targets must be identified and the synthesis of novel curative agents is 
required. Downstream signaling molecules of AR including p66Shc, ErbB-2, AKT, and 
ERK have the potential to be useful alternative targets for inhibition either alone, or in 
combination with AR or other proteins. Figure 1.5 summarizes these signaling pathways. 
Therefore the following studies investigate the effects of novel therapeutic compounds 
on these proteins’ signaling pathways as well as their ability to promote PCa cell growth 
and development. We also seek to further elucidate the mechanism through which 










Figure 1.1 Prostate cancer progression over time.  
Most prostate cancer arises from prostate epithelial cells and is thus regulated by 
androgen signaling. Initially, localized prostate cancer is effectively treated by surgery 
or radiation therapy. However, once the tumor returns or begins to invade 
surrounding tissues and metastasize, androgen deprivation therapy (ADT) by means 
of chemical or physical castration is used to treat the patient. At this point the tumor 
will typically go into remission for a period of 3 to 5 years or longer. However, the 
majority of patients eventually relapse and develop “hormone-refractory” or 
“castration-resistant” tumors which are unresponsive to ADT. Typically, while ADT is 
ineffective, tumors are still regulated by androgen-receptor activation, thus anti-
androgen agents such as abiraterone acetate or enzalutamide can be used to treat 
some patients. Alternatively chemotherapeutic agents such as docetaxel and 
prescribed. Unfortunately, these methods only extend patient survival by an average 








Figure 1.2 Mechanism of androgen signaling and androgen deprivation 
therapy.  
In the male body, the pituitary gland releases luteinizing hormone which stimulates 
Leydig cells in the testes to produce androgens. These are then distributed 
throughout the body via the bloodstream in the form of testosterone. Upon entering 
prostate epithelial cells, testosterone is converted to dihydrotestosterone (DHT) by 
5α-reductase it the cytosol. AR, which is normally bound by heatshock proteins 27 
and 90 in the cytosol, is released upon binding DHT, allowed to form dimers, and 
enter the nucleus where it acts as a transcription factor for multiple proteins essential 
to cell growth, migration, and survival. In the absence of androgens, prostate 
epithelial cells undergo apoptosis, thus in the early stages of prostate cancer 
androgen deprivation therapy ADT is very effective at reducing tumor volume. 
Androgen deprivation therapy consists of reducing the body’s circulating levels of 













Figure 1.3 The Shc1 gene 
The Shc1 gene is localized on chromosome 1 and contains 12,066 base-pairs of 
DNA, including 13 exons and 13 introns. The Shc1 locus contains two distinct 
promoters. The first regulates expression of isoforms p52Shc and p46Shc that are 
separated by two different in-frame ATG codons and which spice-out part of the first 
coding exon contained in p66Shc. The second promoter prevents partial loss of the 










Figure 1.4 Molecular domain schematic of p66Shc protein structure.  
All three Shc isoforms (p66, p52, p46) possess C-terminal Src homology 2 (SH2), 
collagen homology 1 (CH1), and phosphotyrosine binding (PTB) domains. p66Shc 
has additional  cytochrome c-binding (CB) and N-terminal collagen homology 2 (CH2) 
domains. Rac1 activates p38, which induces phosphorylation of S54 and T386  
suppresses ubiquitination and degradation of p66Shc. S36 phosphorylation promotes 





Figure 1.5 Summary prostate cancer signaling schematic  
In prostate cancer, AR is activated upon binding DHT and induces stabilization of 
p66Shc. p66Shc then enters the mitochondria, oxidizing cytochrome C, and inducing 
generation of ROS which oxidize and inactivate various cytoplasmic phosphatases, 
including PTEN and cPAcP. cPAcP is then incapable of dephosphorylating ErbB-2, 
which leads to hyper activation of ErbB-2 and increased activation of ErbB-2 
downstream targets including, Rac1, the Ras/Raf/MEK/ERK cascade, and PI3K. 
Inhibition of PTEN and activation of PI3K lead to increased concentrations of PIP3 
and activation of AKT. AKT can directly phosphorylate AR, increasing its activity, as 
well as induce cholesterol production which some CR PCa cells can use to 
synthesize androgens de novo, further activating AR. Statins are a class of 
compounds which inhibit cholesterol synthesis and de novo androgen production. 
Similarly, ERK can directly phosphorylate AR, increasing its activity, as well as 
activate transcription factors that increase AR gene transcription. Finally, while Rac1 
an be activated by ErbB-2, it can also be directly activated by ROS or indirectly by 
p66Shc via SOS1. Rac1 can also contribute to ROS generation via binding and 
activating NOX proteins. Together, these proteins enhance each other’s activation 
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RPMI 1640 medium, Keratinocyte SFM medium, DMEM medium, 2’,7’ –
dichlorofluorescin diacetate (DCFDA), gentamicin, anti-p66Shc (#180S0105A) Ab, 
rhodamine phalloidin, and L-glutamine were purchased from Invitrogen (Carlsbad, CA). 
FBS and charcoal-treated FBS were obtained from Atlanta Biologicals (Lawrenceville, 
GA). Molecular biology-grade agarose was procured from Fisher Biotech (Fair Lawn, 
NJ). Protein molecular weight standard markers, acrylamide, and Bradford protein assay 
kit were purchased from Bio-Rad (Hercules, CA). Docetaxel was purchased from Aventis 
Pharmaceutical Products Inc. (Collegeville PA). Anti-AR (#C1411, 1:400), Anti-CDC25B 
(#D2810, 1:1000), anti-cyclin B1 (#K1907, 1:1000), anti-cyclin D1 (#A2712, 1:1000), anti-
BclXL (#F111, 1:1000), anti-Bax (#G241, 1:1000), anti-PCNA (#G261, 1:3000), anti-p53 
(#K2607, 1:1000), anti-PSA (#E1812, 1:2000), anti-Survivin (#C271, 1:2000), anti-
phospho-ErbB-2 (Y1221/2) (#B2212, 1:1000), anti-ErbB-2 (#E3110, 1:1000), and 
horseradish peroxidase-conjugated anti-mouse (#C2011, 1:5000), anti-PAcP (#D0209, 
1:1000), anti-PYK2 (#F061, 1:1000), anti-Rac1 (#G1905, 1:1000), anti-rabbit (#D2910, 
1:5000), anti-goat (#J0608, 1:5000) IgG Abs, and AKT inhibitor (MK2206) were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-AKT (Ser473) (#GA160, 
1:1000), anti-AKT (#C1411, 1:2000), anti-FOXM1 (#5436S, 1:500), anti-HA-Tag 
(#C29F4, 1:3000), anti-phospho-mTOR Ser2448 (#5536S, 1:1000), anti-mTOR 
(#2972S, 1:1000), anti-Caspase 3 (#9665S, 1:1000), anti-PARP (#9532S, 1:1000), anti-
phospho-p38 (T180/Y182) (#9211S, 1:1000), and anti-Snail (#3895S, 1:1000), anti-
phospho-Stat5 (Y694) (#9351S, 1:4000), and anti-Stat5 (#9363, 1:2000) Abs were from 
Cell Signaling Technology (Beverly, MA). Anti-HO-1 (#Z04608d, 1:1000) Ab was 
obtained from ENZO Life Sciences (Farmingdale, NY). Anti-Nrf2 (ab62352, 1:1000) Ab 
was obtained from Abcam (Cambridge, UK). Anti-GTP-Rac1 (#G052YWF2, 1:1000) Ab 
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was obtained from New East Biosciences (Malvern, PA). Anti-β-actin (#99H4842, 
1:10000), anti-NOX5 (#3116867, 1:1000) Abs, atorvastatin, DHT, propidium iodide, and 
simvastatin were procured from Sigma (St. Louis, MO). Anti-phospho-PYK2 Y402 
(#CDRO0114121, 1:1000) Ab was obtained from R&D Systems (Minneapolis, MN). Anti-
Shc (#06-203, 1:5000) Abs was obtained from Upstate Biotech. Inc. (Lake Placid, NY). 
Anti-β-actin (#99H4842, 1:10000) Ab, FOXM1 inhibitor (FDI-6), Rac1 inhibitor (EHop-
016), PYK2 inhibitor (PF-431396), mTOR inhibitor (Rapamycin), N-acetyl-cysteine 
(NAC), hydrogen peroxide (H2O2) was procured from Sigma (St. Louis, MO). DAPI Hard-
Mount Medium was obtained from Vector Laboratories (Burlingame, CA). ErbB-2 
inhibitor (AG879), PI3K inhibitor (LY-294002), and ERK inhibitor (PD-9805) were 
obtained from Calbiochem (San Diego, CA).  
Imidazopyridine derivatives HIMP (3-phenyl-1-(pyridine-2-yl)imidazo[1,5-
a]pyridine), M-MeI (1-(pyridine-2-yl)-3-(m-tolyl)imidazo[1,5-a]pyridine), OMP (1-(pyridine-
2-yl)-3-(o-tolyl)imidazo[1,5-a]pyridine), and EtOP (3-(4-ethoxyphenyl)-1-(pyridine-2-
yl)imidazo[1,5-a]pyridine) were synthesized and provided by Dr. Xiu Bu as previously 
described [1,2]. Statin derivative compounds [simvastatin hydroxyacid] (SVA), [8-(3,5-
dihydroxy-7-((2-(2-hydroxyethoxy)ethyl)amino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-
hexahydronaphthalen-1-yl 2,2-dimethylbutanoate] (AM1), and [8-(3,5-dihydroxy-7-((2-(2-
hydroxy)ethyl)amino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 
2,2-dimethylbutanoate] (AM2) were provided by Dr. Chen’s laboratory, and synthesized 
based on the structure of simvastatin. For ease of reading, chemical abbreviations are 
used throughout the text. 
2.2 Cell Culture 
Human prostate carcinoma cell lines LNCaP, MDA-PCa2b, VCaP, PC-3, and 
DU145 cells were originally purchased from the American Type Culture Collection 
40 
 
(Rockville, MD, USA). LNCaP, PC-3, and DU145 were routinely maintained in RPMI 
1640 medium containing 5% FBS, 2 mM glutamine, and 50 µg/ml gentamicin [3-6]. MDA 
PCa2b cells were maintained in BRFF-HPC1 medium containing 20% FBS, 2 mM 
glutamine and 50 µg/ml gentamicin [7-8]. As reported previously, we established LN-AI 
(C-81) and MDA-AI cells which obtain many biochemical properties of clinical CR PCa 
including the expression of functional AR as well as PSA secretion and rapid cell 
proliferation in androgen-depleted conditions [4-6,9]. LNCaP-AI cells also possess the 
enzymatic capacity to synthesize androgens from cholesterol. Most importantly, both AI 
cell lines have elevated basal growth rates as well as increased levels of p66Shc protein 
compared to their respective AS cell lines [3]. VCaP cells were maintained in DMEM 
medium containing 15% FBS, 2 mM glutamine, 50 µg/ml gentamicin, and 10 µg/ml 
ciprofloxacin [9,10]. RWPE1 cells were cultured in Keratinocyte-SFM supplemented with 
bovine pituitary extract (25 µg/ml) and recombinant epidermal growth factor (0.15 ng/ml) 
along with 50 µg/ml gentamicin. To mimic conditions of clinical ADT, cells were 
maintained in SR conditions, i.e., phenol red-free RPMI 1640 medium containing 5% 
charcoal/dextran-treated FBS, 2 mM glutamine, 50 µg/ml gentamicin, and 1 nM DHT. 
Imidazopyridine derivatives HIMP, M-MeI, OMP, and EtOP were dissolved in DMSO at 
20 mM stock concentrations, stored at -20°C and diluted as needed for experimental 
conditions in the respective medium. Statin derivatives simvastatin, SVA, AM1, and AM2 
were dissolved in DMSO at 20 mM stock concentrations, stored at -20°C, and diluted as 
needed for experimental conditions in the respective medium. 
2.3 Preparation of Cell Lysates and Immunoblot Analysis 
 All cells were rinsed with ice-cold HEPES-buffered saline, pH 7.0, harvested via 
scraping, and lysed in ice-cold lysis buffer containing protease and phosphatase 
inhibitors. Total cellular lysates were prepared as previously described [8,11]. The 
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protein concentration of the supernatant was determined using a Bio-Rad Bradford 
protein-assay. For immunoblotting, an aliquot of total cell lysate was electrophoresed on 
SDS-polyacrylamide gels (7.5%-12%). After being transferred to nitrocellulose 
membrane, membranes were blocked with 5% non-fat milk in Tris-buffered saline 
containing 0.1% Tween-20 for 30 minutes at room temperature. Membranes were 
incubated with the corresponding primary Ab overnight at 4°C. Membranes were then 
rinsed and incubated with the appropriate secondary Ab for 60 minutes at room 
temperature. Proteins of interest were detected by an ECL reagent kit and β-actin was 
used as a loading control. The intensity of the protein bands were analyzed with ImageJ 
software [8]. 
2.4 Trypan Blue Exclusion and Membrane Permeability Assays 
For cell proliferation experiments under regular conditions, cells were seeded in 
regular culture medium and allowed to attach for 3 days, then changed to fresh medium 
containing the respective statin compounds and cultured for an additional 3 days. To 
determine cell proliferation under SR conditions, all cells were seeded in regular 
conditions and allowed to attach for 3 days. Cells were then steroid-starved for 48 hours 
in SR medium, and changed to fresh SR medium containing the noted  compound(s) 
and cultured for an additional 3 days. Control groups received solvent DMSO alone. 
Cells were harvested via trypsinization and live cell numbers were counted by Trypan 
Blue dye exclusion assay using a Cellometer Auto T4 Image-based cell counter 
(Nexcelom, MA, USA). To determine cell membrane integrity, cells were treated as 
described above and a ratio of blue-stained cells to total counted cells was determined. 
2.5 Clonogenic Assay 
The clonogenic cell growth assay was conducted as described previously [12-
13]. Briefly, LNCaP C-81 cells were plated on the plastic surface of 6-well plates under 
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regular culture conditions at a density of 2,000 cells per well. Cells were incubated 
overnight, the unattached cells were removed and remaining cells were fed with fresh 
regular medium containing 20 µM statin-compounds. Cells were grown for 9 days with a 
change of fresh medium every 3 days. On the 10th day, the medium was removed and 
cells were washed with ice-cold HEPES-buffered saline, then attached cells were 
stained with a 0.2% crystal violet solution containing 50% methanol and counted. 
2.6 Soft Agar Assay 
The effect of statin agents on anchorage-independent LNCaP C-81 colony growth was 
assessed by soft agar assay. Briefly, 5 x 104 cells were seeded into a 0.25% agarose top 
layer with a base layer containing 0.3% agarose in 35mm dishes. The day after seeding, 
cell clusters containing more than one cell were excluded from the study. Cells were 
then fed with 0.5 mL of fresh regular medium containing the respective statin-agent 
every 3 days for 6 weeks. The colonies were then stained with a 0.2% crystal violet 
solution containing 50% methanol and counted. 
2.7 Transwell Assay 
 Cell migration was assessed via Boyden Chamber transwell assay as described 
previously [14,15]. Cells were plated at a density of 5 x 104 cells into the upper chamber 
of 24-well plate transwell inserts and allowed to migrate for 24 hours. In experiments 
with small molecule inhibitors, inhibitor compounds were added to the bottom chamber 
for a final concentration of their IC50 in LNCaP cells prior to the addition of cells. After a 
24-hour incubation, cells were stained with 0.2% crystal violet solution in 50% methanol 
and cells remaining in the upper chamber were removed via cotton swab. Cells which 
had migrated to the lower chamber were counted at 40x magnification under a 
microscope. For experiments using small molecule inhibitors, to distinguish cell 
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migration from cell growth the results were normalized to growth inhibition in which 24-
hour change in cell migration was divided by 24-hour change in cell growth. 
2.8 Cell Adhesion Assay 
To determine the effect of imidazopyridine derivatives on PCa cell adhesion to plastic-
ware surfaces, LNCaP C-81 cells were suspended in 5% FBS 1640 RPMI medium 
containing 10 µM of respective compounds and incubated for 30 minutes. Cells were 
then plated in 6-well plates in triplicates at a density of 3x103 cells/cm2 in respective 
treatment medium and incubated for an additional hour. Non-attached cells were 
carefully washed away and the remaining attached cells were stained with a 0.2% 
crystal violet solution containing 50% methanol. The total number of cells in five fields at 
40x magnification per well were counted. 
2.9 Flow Cytometry Analysis 
2.9.A DCF-DA Assay 
Changes in cellular ROS levels induced by statin-compounds in LNCaP C-81 cells were 
determined via DCF-DA dye analysis [16]. Cells were plated in triplicate at a density of 2 
x 104 cells per well using 6-well plastic plates and grown under regular conditions for 3 
days. Cells were then steroid starved for 48 hours in SR medium before being changed 
to fresh SR medium containing the noted  treatment compound(s) and cultured for an 
additional 3 days. Control groups received solvent DMSO alone. Cells were harvested 
and incubated with medium containing 20 µM DCF-DA dye. Determination of cell cycle 
distribution and DCF-DA fluorescence was carried out using the Becton-Dickinson 
fluorescence-activated cell sorter (FACSCalibur, Becton Dickinson, San Jose, CA, USA) 




2.9.B Propidium Iodide Assay 
To determine the compounds’ effects on cell cycle, flow cytometry analysis was 
conducted as previously described [12]. Briefly, LNCaP C-81 cells were seeded in T25 
flasks at a density of 5 x 104 cells in regular medium for 3 days, changed to SR medium 
for 48 hours, and then fed with fresh SR medium containing 20 µM of the specified 
compound. Cells were harvested after 3 days of treatment, fixed with 70% ethanol, and 
stained using Telford Reagent at 4°C for 4 hours [17].  
2.10 Determination of Cellular Cholesterol 
The level of cellular cholesterol was determined using the Abcam cholesterol 
assay kit [18]. Briefly, LNCaP C-81 cells were plated in 96-well plates at a density of 2 x 
104 cells per well and allowed to attach overnight. Cells were treated with medium 
containing 20 µM statin derivatives or solvent alone for 3 days. The medium was then 
removed and cells were fixed for 10 minutes, followed by 3x wash with cholesterol 
detection buffer for 5 minutes. In the absence of light, cells were then stained with Filipin 
III for 1 hour and washed 2x for 5 minutes. Staining was examined via a fluorescence 
microscope and the relative fluorescence was quantified using Ziess-provided imaging 
program Zen lite 2012. 
2.11 Protein Microarray 
 Cell lysates were prepared from an equally mixed population of stable p66Shc 
cDNA-transfected subclones and V1 vector-alone control cells as previously described 
and sent to Kinexus Protein Profiling Services (Vancouver, BC) where the company 
performed analysis via the KAM-900P microarray. Results are reported in the format of 




2.12 Confocal Microscopy and F-actin Staining 
 Cells were plated on sterile round coverslips at 3x104 cells per coverslip and 
allowed to attach for 24 hours. Cells were then washed with pre-warmed phosphate-
buffered saline and fixed with a 3.7% formaldehyde solution for 10 minutes at room 
temperature. Cells were then washed, permeabilized with 0.1% Triton X-100 solution for 
5 minutes, and again washed before blocking with 1% BSA solution for 30 minutes. At 
this time, cells were stained with fluorescent phallotoxins, which directly binds to F-actin, 
in 1% BSA for 20 minutes followed by washing. To stain HA-tagged DN Rac1 
transfected cells, cells were then incubated with primary anti-HA-tag Ab in 1% BSA for 1 
hour, followed by washing and secondary Ab incubation for 30 minutes and a final wash. 
Coverslips were then mounted using VectorShield hard-mount medium containing DAPI 
stain and allowed to set overnight before images were captured via confocal microscopy 
[14]. The relative area of cell lamellipodia to total cell area was semi-quantified using 
NIH ImageJ software. Results were repeated in three separate experiments in which 20 
cells were quantified (For a total of 60) for each cell-line/treatment [19]. 
2.13 cDNA and shRNA Transfection 
 For transient transfection experiments, LNCaP cells were plated at a density of 
1x104 cells per cm2 and transfected using Lipofectamine and Plus reagents. Five hours 
after transfection, the cells were fed with RPMI medium containing 10% FBS for 24 hrs. 
The cells were then used for transwell assays and whole cell lysates harvested for 
immunoblot analysis. Stable subclones of LNCaP cells overexpressing p66Shc were 
established as described previously [3]. DN (T17N) and CA (G12V) Rac1 cDNA were 
provided by Dr. Yaping Tu’s laboratory [19]. For knock-down of p66Shc expression, 
transient transfection of pSUP-p66 plasmid-based small interfering RNA system targeted 
against the CH2 domain was used for cDNA transfection as described previously [3]. 
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2.14 Immunohistochemical Staining 
 The protocol for the usage of human prostate archival specimens was approved 
by the Institutional Review Board at UNMC. According to tissue availability, we obtained 
37 human prostate cancer archival specimens for analyzing p66Shc expression. Of 
those 37 slides, 33 specimens were identified by H&E staining to contain both benign 
and malignant tissues on the same slide and were used for the direct comparison of 
p66Shc protein level in the two tissue types in the same section, as described in our 
previous study [5]. Immunohistochemical staining was carried out as previously 
described in Lee et. Al. 2004 [20]. The comparison of expression level of p66Shc protein 
in paired samples (benign and malignant) on the same tissue section was analyzed 
using the one population t-test (p<0.05 was considered as significant difference). 
2.15 Statistical Analysis 
 Each set of experiments are conducted in triplicate or duplicate as 
specified in the figure legend, and experiments are repeated independently at least three 
times, denoted as n=3x3. All results are presented as mean ± standard error 
measurement. Correlation coefficient r was calculated using Microsoft Excel. Statistical 
significance was determined using a paired two-tailed student-t test assuming unequal 
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Prostate cancer (PCa) is the third leading cause of cancer-related death afflicting 
United States males.  Most treatments to-date for metastatic PCa includes androgen-
deprivation therapy and the second-generation anti-androgens such as abiraterone 
acetate and enzalutamide. However, a majority of patients eventually develop resistance 
to these therapies and relapse into the lethal, castration-resistant form of PCa to which 
no adequate treatment option remains. Hence, there is an immediate need to develop 
effective therapeutic agents toward this patient population. Imidazopyridines have 
recently been shown to possess Akt kinase inhibitory activity; thus in this study, we 
investigated the inhibitory effect of novel imidazopyridine derivatives HIMP, M-MeI, 
OMP, and EtOP on different human castration-resistant PCa cells. Among these 
compounds, HIMP and M-MeI were found to possess selective dose- and time-
dependent growth inhibition: they reduced castration-resistant PCa cell proliferation and 
spared benign prostate epithelial cells. Using LNCaP C-81 cells as the model system, 
these compounds also reduced colony formation as well as cell adhesion and migration, 
and M-MeI was the most potent in all studies. Further investigation revealed while HIMP 
primarily inhibits PCa cell growth via suppression of PI3K/Akt signaling pathway, M-MeI 
can inhibit both PI3K/Akt and androgen receptor pathways and arrest cell growth in the 
G2 phase. Thus, our results indicate the novel compound M-MeI to be a promising 
candidate for castration-resistant PCa therapy, and future studies investigating the 







3.2 Background and Rationale 
Prostate cancer (PCa) remains the most commonly diagnosed solid tumor and 
the third leading cause of cancer-related death in United States men, maintaining a need 
for new effective treatment options [1]. Currently, androgen-deprivation therapy (ADT) is 
the standard course of treatment for metastatic PCa, however, most PCa patients 
relapse within 1-3 years and develop CR PCa which is unresponsive to ADT [2,3,4]. In 
2004, a combination of docetaxel and prednisone was shown to increase patient median 
survival by 2-3 months, making it the standard-of-care treatment for CR PCa [5]. 
Recently, the FDA has approved additional compounds such as novel taxane 
chemotherapeutic cabazitaxel [6], androgen synthesis inhibitor abiraterone acetate [7], 
AR signaling inhibitor enzalutamide [8], immunotherapeutic sipuleucel-T [9], and bone 
micro-environment-targeted radiopharmaceutical alpharadin (Radium-223) for treating 
CR PCa [10].  However, these treatment options are only able to prolong survival by a 
few months and the average period of CR PCa patient survival remains less than two 
years [11]. Despite advancements in post-ADT treatment strategies, CR PCa remains an 
incurable disease; thus there is a great need for alternative therapeutic options. 
While androgen insensitivity can be manifested in multiple ways; one proposed 
alternative mechanism is the increased activation of Akt signaling under androgen 
deprived conditions. Akt is known to regulate cell cycle, metabolism, angiogenesis, and 
cell survival in PCa and its activation may contribute to tumor resistance to ADT and 
anti-androgens [12,13]. One mechanism through which Akt may contribute to PCa 
survivability is via modulation of AR signaling. In addition to inducing cell growth, AR 
also has a role in regulating apoptosis. Upon phosphorylation of AR at Ser-210 and Ser-
790 by Akt, AR-mediated apoptosis is suppressed. Through this mechanism, enhanced 
Akt activity in PCa may contribute to PCa survivability upon ADT [13]. Indeed, genetic 
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loss and/or mutations in the PI3K/Akt pathway that lead to signal deregulation may 
present in up-to 42% of primary prostate tumors and over 90% of metastatic tumors, 
making it a priority next-in-line therapeutic target [14]. Recently, investigations into 
imidazopyridines, a novel class of compounds containing aromatic aldehydes and a 
pyridine group, have demonstrated these compounds possess potent Akt kinase 
inhibitory activity [15-17]. Data shows these compounds have an anti-proliferative effect 
against CR PCa cells with the ability to simultaneously inhibit AR and PI3K/Akt/mTOR 
signaling pathways, making them promising therapeutic agents [18]. 
To investigate imidazopyridines’ efficacy for PCa therapy, the LNCaP 
progressive cell model, originally characterized in Lin et. al. JBC 1998, was used as the 
primary cell model in this study. LNCaP C-81 cells are AI, express PSA in the absence 
of androgens, and gain the ability to synthesize testosterone from cholesterol under SR 
conditions [19-22]. C-81 cells also possess enhanced proliferation, ability to form 
colonies, and migratory potential [21,23]. Most Importantly, LNCaP C-81 cells retain AR 
expression and correspond to the expression of AR in the majority of PCa as well as 
advanced CR PCa [19]. This makes them a superior cell model for therapeutic studies 
when compared to many other PCa cell lines. Other cell lines selected for this study 
include MDA PCa2b-AI, PC-3, and RWPE1. Upon passage, MDA PCa2b cells behave 
similarly to LNCaP cells and shift from AS at low passage to AI at high passage. MDA 
PCa2b-AI (MDA-AI) cells also retain AR expression and possess enhanced 
tumorgenicity; this makes MDA-AI and LNCaP C-81 preferable cell models for studying 
prostate adenocarcinoma. Further, due to the ability of imidazopyridine derivatives to 
target both Akt and AR pathways, it is prudent to investigate the compounds’ effects on 
AR-negative PC-3 cells to determine their efficacy in cells which lack classic androgen 
signaling mechanisms. In addition, PC-3 cell lines are more representative of small-cell 
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neuroendocrine carcinoma than more clinically predominant adenocarcinoma [24]; 
therefore this cell line should be used in conjunction with models such as LNCaP and 
MDA PCa2b cell lines to expand clinical utility. Finally, immortalized benign prostate 
epithelium RWPE1 cells act as a control to gauge the selectivity of the imidazopyridine 
derivative compounds (Fig. 3.1). Thus our cell models clearly represent the majority of 
molecular events observed in clinical implementations of modern PCa therapies. 
Our results demonstrate these imidazopyridine derivatives are able to suppress 
human PCa cell proliferation in a dose- and time-dependent manner. Importantly, 
compound M-MeI exhibited selective potency against CR PCa cell proliferation in 
comparison to benign prostate epithelial cells. Furthermore, this compound was also 
found to inhibit cell migration, adhesion, and in vitro tumorigenicity. Our data is the first 
to demonstrate the anti-tumor effect of novel imidazopyridine derivatives HIMP, M-MeI, 
OMP, and EtOP on CR PCa cells and indicates M-MeI to be a promising lead 
therapeutic agent for future studies. 
3.3 Results 
3.3.A Dose-Dependent Effect of Imidazopyridine Derivatives on CR PCa cell 
Proliferation 
LNCaP C-81 cells exhibit many biochemical properties as seen in clinical CR 
PCa, including functional AR expression, AI PSA secretion, and proliferation with 
intracrine growth regulation [19,21-23] and thus were used as the primary cell model 
system for testing imidazopyridine compounds. Initially, the dose-dependent effects of 
HIMP, M-MeI, OMP, and EtOP on LNCaP C-81 cells were tested under regular culture 
conditions. Cells were treated with 0-10 µM of each compound for 72 hours and cell 
growth was analyzed via Trypan Blue exclusion assay. Under regular culture conditions, 
dose-dependent inhibition of cell proliferation was observed for all compounds with 
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estimated IC50 values of 6.1 µM (M-MeI), 6.6 µM (EtOP), 7.3 µM (OMP), and 9.3 µM 
(HIMP) (Fig. 3.2A).  
We then examined the effect of the compounds in SR conditions, mimicking ADT 
conditions. The compounds inhibited cell growth following the dosage response with 
estimated IC50 values of 10.2 µM (M-MeI), 10.5 µM (OMP), 11.6 µM (HIMP), and 16.0 
µM (EtOP) (Fig. 3.2A).  Interestingly, M-MeI had the greatest inhibitory activity under 
both growth conditions. Though EtOP had comparable inhibition to M-MeI in regular 
conditions, it had the least effect under SR conditions. HIMP and OMP were also shown 
to be less effective than M-MeI under both treatment conditions.  
3.3.B Selective Anti-Proliferative Effect of Compounds on PCa vs. Immortalized 
Normal Prostate Epithelial Cells 
The suppressive effect of each inhibitor on proliferation was investigated using a panel 
of cancerous and benign prostate epithelial cell lines. AI PCa cells including AR-positive 
LNCaP C-81 and MDA PCa2b-AI as well as AR-negative PC-3 cells were chosen as 
representatives of advanced CR PCa. RWPE1 cells, an immortalized benign prostate 
epithelial cell line, were used to determine the compounds’ selectivity. After three days of 
10 µM treatment under SR conditions, HIMP, M-MeI, and EtOP all displayed selective 
inhibition of proliferation of cancerous cells with significantly less effect on non-
cancerous RWPE1 cells (Fig. 3.2B).  Though OMP was effective against C-81 and PC-3 
cells, it was comparatively potent against RWPE1 cells. Overall, the results show HIMP 
and M-MeI were the most selective, inhibiting PCa cell growth significantly more than 





3.3.C Suppression of PCa Tumorigenicity by Imidazopyridine Derivatives 
The compounds’ ability to suppress colony formation in LNCaP C-81 cells was 
initially accessed by in vitro clonogenic assays for anchorage-dependent cell growth. 
LNCaP C-81 cells were seeded with 20, 200, and 2,000 cells per well in 6-well plates, 
and then treated with 10µM of each compound. Upon 10-days of treatment, all 
compounds significantly inhibited clonogenic growth at 2,000 cells per well as shown in 
Fig. 3.3A for 2,000 cells per well. While M-MeI and EtOP strongly inhibited colony 
growth, HIMP and OMP were comparatively less potent. Minimal colony formation was 
observed at densities of 20 and 200 cells per well. 
 The soft agar colony formation assay was then performed to determine the 
compounds’ effect on anchorage-independent growth in a 3-dimentional environment. 
As shown in Fig. 3.3B, cells cultured at a density of 5,000 cells per 35 mm dish for four 
weeks produced far fewer colonies with smaller colony size when treated with the 
imidazopyridine derivatives. Compared to control cells treated with solvent alone, M-MeI 
suppressed colony growth to the greatest extent, reducing the number of colonies by 90 
percent with barely visible colony size (Fig. 3.3B). In comparison, EtOP and OMP 
reduced colony growth with 80 and 70 percent inhibition, respectively, and HIMP had the 
least effect at about 50 percent inhibition.  
To clarify whether these compounds’ effect on colony formation is in part due to 
the inhibition of cell adhesion, the capacity of HIMP, M-MeI, OMP, and EtOP to influence 
PCa cell adhesion onto the plastic surface of 6-well plates was then investigated. While 
these compounds had varying degrees of suppression on the ability of LNCaP C-81 cells 
to adhere at a density of 50,000 cells per well, a similar inhibitory trend was observed to 
that of clonogenic and soft agar assays (Fig. 3.3C vs. 3.3A &3.3B).  M-MeI had the 
greatest effect and was able to reduce cell attachment by about 40 percent. While HIMP 
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and EtOP were also able to significantly inhibit cell adherence, they did so to a lesser 
extent; OMP was found to have a minimal effect on the C-81 cells’ ability to attach to the 
plastic surface. Hence, though all compounds belong to the same class of molecules, 
they influence PCa cell colony formation and adhesion differently. 
To investigate the inhibitory ability of these compounds on tumor metastasis, 
their activity on cell migration was analyzed by transwell migration assay. Interestingly, 
these compounds were found to have varying degrees of suppression on PCa cell 
migration. Fig. 3.3D showed that both M-MeI and EtOP were able to significantly reduce 
LNCaP C-81 cell migration via Boyden Chamber assay over a period of 24 hours by 
about 30 percent. Comparatively, HIMP and OMP failed to significantly reduce cell 
migration. Overall, M-MeI was found to exhibit the most potent inhibitory activity on CR 
PCa cell tumorgenicity. 
3.3.D Effect of Imidazopyridine Compounds on Proliferative and Apoptotic 
Signaling in CR PCa Cells 
It is well established that the majority of CR PCa cells express functional AR 
which is still required for their growth and survival [22,31,32]. To determine how the 
compounds suppress PCa cell proliferation, we analyzed their effects on proliferative 
and apoptotic signaling in AR-positive LNCaP C-81 and MDA PCa2b-AI cells under SR 
conditions. Figs. 3.4A and 3.4B showed that, upon 3-day treatments, 10µM of each 
compound significantly suppressed LNCaP C-81 and MDA PCa2b-AI cell proliferation.  
In LNCaP C-81 cells under SR conditions, though imidazopyridines are known 
for Akt inhibition, only HIMP and M-MeI inhibited Akt activation as shown by decreased 
Ser473 phosphorylation (Fig. 3.4C) [15]. Additionally, while all compounds reduced AR 
protein levels in LNCaP C-81 cells; M-MeI and EtOP were more potent. Importantly, a 
similar trend was observed in AR-regulated pro-proliferative proteins. M-MeI and EtOP 
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reduced levels of p66Shc, a 66kDa Src-homologous collagen homologue, cyclin D1, and 
PCNA, while HIMP and OMP had minimal effects [33-36]. We also analyzed Stat5 
phosphorylation at Y694, which aids in the translocation of AR to the nucleus and is a 
regulator of cylcin D1 synthesis [37,38]. Unexpectedly, M-MeI slightly increased Stat5 
activation in C-81 cells while EtOP suppressed activation; HIMP and OMP had no effect. 
Though all compounds diminished anti-apoptotic Survivin protein, their treatment 
elevated BclXL, another anti-apoptotic protein [39,40]. The compounds’ effect on p53, a 
regulator of cell survival and inducer of apoptosis, varied with M-MeI slightly lowering 
p53 levels, and EtOP slightly increasing them; HIMP and OMP had no significant effect 
[41]. 
As shown in Fig. 3.4D, in MDA PCa2b-AI cells under SR conditions, AR inhibition 
was similar to that of LNCaP C-81 cells: M-MeI and EtOP greatly suppressed AR levels 
while HIMP and OMP had minimal effects. This also correlated with lower levels of AR-
regulated p66Shc, cyclin D1, and PCNA in M-MeI-treated cells, all of which promote cell 
growth. As seen in C-81 cells, in MDA PCa2b-AI cells HIMP and OMP had no inhibitory 
effect on Stat5 activation, while EtOP suppressed Y695 phosphorylation. M-MeI, 
however, strongly reduced Stat5 phosphorylation in MDA PCa2b-AI cells where it had 
increased it in C-81 cells. Also, while the compounds’ effect on p53 remained similar in 
MDA-AI cells compared to C-81 cells, their effects on anti-apoptotic Survivin and BclXL 
proteins were altered. In MDA-AI cells, HIMP, OMP and EtOP increased levels of 
Survivin while BclXL remained unchanged relative to control cells suggesting these 
proteins are not essential to growth inhibition. Because Akt phosphorylation at Ser473 in 
MDA PCa2b-AI cells was undetectable under SR conditions, these cells were instead 
treated in regular culture medium for three days and all compounds were found to 
reduce Akt activation (Fig. 3.4E). 
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In summary, of the four compounds tested, M-MeI was the most potent inhibitor of 
proliferation in both LNCaP C-81 and MDA PCa2b-AI cell lines under SR conditions. It 
also consistently reduced AR and AR-regulated proteins as well as Akt Ser473 
phosphorylation in both cell lines, suggesting these pathways are involved in 
imidazopyridine inhibition of CR PCa cell growth. 
3.3.E Kinetic Effect of HIMP and M-MeI on LNCaP C-81 Cells under SR Conditions 
Since HIMP and M-MeI exhibited the most selectively potent activity, these two 
compounds were investigated further by kinetic analysis in LNCaP C-81 cells under SR 
conditions for clinical relevance. As shown in Fig. 3.5A, both HIMP and M-MeI began to 
show significant inhibition of cell proliferation on day three of treatment, and this trend 
continued through day seven. It should also be noted M-MeI exhibited greater growth 
suppression than HIMP at every time point analyzed.  
 Cell lysates were collected from each time point and Western Blot analysis was 
performed (Fig. 3.5B). Our results showed M-MeI-treated cells had decreased levels of 
AR and PSA, an androgen-regulated protein, as well as cell cycle proteins cyclin B1 and 
PCNA as seen at 5-day treatment. Meanwhile, HIMP treatment decreased PSA protein 
level upon 7-day treatment but not AR protein level. A similar trend was observed in pro-
proliferation proteins as HIMP had no effect on cyclin B1 and marginal effect on PCNA.  
It should be noted, as the level of active unphosphorylated cyclin B1 decreased (lower 
band), the inactive phosphorylated cyclin B1 protein level increased (upper band) [42]. 
The data may indicate arrestment of the cell cycle.  
 We also investigated the effects of HIMP and M-MeI on pro-apoptotic proteins 
Bax as well as p53 vs. anti-apoptotic Bcl-XL [40]. Treatment with both compounds 
dramatically increased Bax and p53 protein level by day seven and correlated with the 
observed decrease in cell proliferation. Interestingly, both compounds initially increased 
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Bcl-XL levels on days one and three, and had no effect on Bcl-XL as treatment continued 
(Fig. 3.4B). Thus both compounds seem to induce apoptosis by increasing levels of pro-
apoptotic proteins instead of inhibiting anti-apoptotic proteins, while M-MeI also reduces 
pro-proliferative proteins as well as AR signaling. 
 To further investigate the kinetic effect of HIMP and M-MeI, cell cycle analysis 
was performed via flow cytometry. The cell cycle analyses (Fig. 3.5C) revealed that upon 
7-day treatment, M-MeI reduced LNCaP cell proliferation by 50% as indicated by the 
decreased percentage of cell population in S phase. M-MeI also increased the 
percentage of cells undergoing apoptosis nearly four-fold at day seven relative to control 
cells. At the same time, HIMP had no significant effect on percentage of cells in S phase 
and increased the percentage undergoing apoptosis two-fold by day seven. Interestingly, 
the population of cells treated with M-MeI, but not HIMP, accumulated in G2 phase 
following the time course of treatment, i.e., only a marginal increase on day 3 and about 
a 50% increase in day 5 (Fig. 3.6). On day-7, the percentage of cells in G2 phase 
doubled to about 49% in M-MeI treated cells compared to 24% in control cells (Fig. 
3.5C). In parallel, on day 7, the HIMP-treated cells were only slightly increased from 
about 24% to 27% in G2-phase. These results clearly indicate M-MeI blocks cell cycle at 
G2 phase. 
3.4 Discussion 
Given the poor 5-year 29% survival rate of metastatic CR PCa patients, there is a 
clear need for advancement in treatment alternatives [14]. First line treatment of PCa 
usually involves ADT by means of surgical castration or chemical castration, such as 
luteinizing hormone-releasing hormone treatment, coupled with anti-androgens. 
Treatment with classic anti-androgens such as flutamide or bicalutamide (Casodex), 
which competitively inhibit androgen binding to AR, can be effective for 1-3 years before 
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patients subsequently become unresponsive and eventually relapse. Relapse can occur 
for a number of reasons such as deregulation of AR cofactors, AR overexpression, 
splicing mutations resulting in constitutively active AR, or mutations allowing AR 
activation by competitive inhibitors [43]. In the case of the latter, upon discontinuation of 
flutamide or bicalutamide treatment, patients often experience a period of anti-androgen 
withdrawal syndrome (AAWS) characterized by a decline in serum PSA levels and tumor 
regression [43,44]. In some cases, these patients will respond to treatment with 
alternative anti-androgens, however, patients will again eventually become unresponsive 
to treatment and develop advanced PCa, commonly referred to as “castration-resistant” 
(CR) [45]. While more effective anti-androgens such as enzalutamide, which possesses 
a 5-fold higher binding affinity to AR compared to bicalutamide, are now available, 
mutations allowing AR activation by enzalutamide have been reported and tumors 
continue to become CR over time [46]. The therapeutic effect of second generation anti-
androgens such as enzalutamide and abiraterone acetate implies most cancer cells, 
which still express functional AR, require AR signaling to evade traditional regulatory 
mechanisms to survive androgen deprivation strategies [7,8,47]. Despite the 
effectiveness of ADT and anti-androgen treatment strategies to delay the progression of 
PCa, many patients still develop the CR phenotype and thus there is an urgent need for 
alternative therapeutic targets to AR. Other signaling pathways, such as the PI3K/Akt-
mediated cell survival pathway, may act to supplement the lack of AR stimulation under 
androgen-deprived conditions, bypassing the effect of ADT. Therefore, in this study we 
investigate novel therapeutic agents which are capable of targeting multiple biochemical 
pathways critical to CR PCa cell growth and progression. 
In this study, four novel imidazopyridine derivatives were investigated to 
determine their viability as therapeutic agents for CR PCa. LNCaP C-81 cells were 
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chosen as our primary experimental cell model because they possess many biochemical 
properties common to CR PCa, including expression of functional AR, AI PSA secretion 
and proliferation, and expression of enzymes required for the synthesis of androgens 
from cholesterol [19,21,22,31,47]. We initially showed that all four compounds are 
effective inhibitors of CR PCa cell growth in the LNCaP C-81 cell line model, though to 
varying degrees with M-MeI as the most potent under both regular and SR conditions 
(Fig. 3.2A). Additionally, the effects of the imidazopyridine derivatives on cell proliferation 
differed between compounds as well as cell lines. Of those compounds investigated, 
HIMP and M-MeI displayed broad-spectrum growth inhibition of multiple CR PCa cell 
lines, including both AR-positive and AR-negative cells. Most importantly, these 
compounds exhibited more potent inhibition of proliferation in PCa cells than benign 
RWPE1 cells (Fig. 3.2B).  
We further investigated the effects of each compound on various biological 
activities critical to malignant tumor progression. Colony formation, cell adhesion, and 
migration are vital malignant processes exhibited by many cancer cells. In both 
anchorage-dependent and anchorage-independent growth assays, M-MeI and EtOP 
dramatically reduced the number of colonies formed as well as colony size. This may 
partially be due to M-MeI and EtOP’s ability to inhibit cell adhesion. To investigate the 
effect of these compounds on cell migration, the transwell migration assay was used to 
analyze LNCaP C-81 cell motility. Again, M-MeI and EtOP were found to be potent 
inhibitors of C-81 cell migration while HIMP and OMP had no significant effect. 
Interestingly, this correlates with M-MeI and EtOP’s ability to reduce AR protein level as 
shown in Fig. 3.4C where HIMP and OMP fail to influence AR. This suggests AR 
inhibition may be crucial for the inhibition of these malignant processes. However, while 
EtOP was an effective inhibitor of PCa tumorgenicity, it was not as effective at growth 
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suppression as M-MeI. This may be due to EtOP’s failure to prevent Akt activation 
whereas M-MeI successfully inhibits Akt phosphorylation at S473 (Fig. 3.4C). 
 The PI3K/Akt signaling pathway is proposed to be pivotal to the growth and 
survival of CR PCa cells; dysregulation of this pathway is shown to contribute to 
resistance to treatment [31,48-54]. In clinical studies, for example, treatment with AR 
inhibitor bicalutamide is shown to progressively increase Akt signaling in patients in 
correlation with their Gleason grades [51]. In parallel, PCa treated with 
chemotherapeutic agent docetaxel possess increased Akt activation in patient tumors 
[52]. Other in vitro studies similarly demonstrated LNCaP cells grown in SR medium for 
extended periods of time have increased Akt activation which may compensate for a 
lack of androgen signaling [12]. Indeed, the PI3K/Akt/mTOR pathway is highly activated 
in CR PCa and emerging studies show inhibitors targeting the PI3K/Akt pathway are 
rapidly entering into clinical trials [14,53-55]. Therefore, the PI3K/Akt signaling axis is a 
promising next-in-line therapeutic target and its inhibition in conjunction with ADT and 
anti-androgens may improve patient survival. 
Initially, imidazopyridines have been shown to possess Akt kinase inhibitory 
activity and are effective suppressors of tumor growth and advancement in a number of 
carcinomas, including PCa [15,16,18].  Interestingly, while all four derivative compounds 
inhibited Akt phosphorylation at Ser473 in MDA PCa2b cells; only HIMP and M-MeI 
inhibited its phosphorylation in LNCaP C-81 cells. It should be noted because Akt 
signaling in MDA PCa2b-AI cells was too weak to detect under SR conditions, it was 
observed under regular conditions. It is thus possible the differential inhibition of Akt 
activation in MDA-AI vs. LNCaP C-81 cells was in part due to the difference between 
regular and SR growth conditions (Figs. 3.4C-E).  
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While HIMP is a strong inhibitor of Akt activation in both cells, it fails to 
consistently down-regulate AR, a long established target of PCa therapy. Supportively, 
western blot analysis showed HIMP inconsistently affects AR protein levels (Figs. 3.4D 
and 3.5B), a phenomena which has previously been observed when CR PCa cells are 
treated with PI3K/Akt inhibitors [12,18]. Furthermore, HIMP had little shift in potency 
between regular conditions and SR conditions (Fig. 3.2A), suggesting HIMP’s 
mechanism of inhibition is relatively androgen-independent. In addition, HIMP is a potent 
inhibitor of Akt phosphorylation at Ser473 and also acts to induce pro-apoptotic p53 and 
Bax proteins (Figs. 3.4C, 3.4D & 3.5B) [27]. Together, these results suggest HIMP 
inhibits CR PCa growth by suppressing cell survivability but not androgen signaling.  
While both HIMP and M-MeI were found to have promising selective growth 
suppression, M-MeI was shown to have greater efficacy (Figs. 3.2 and 3.4). M-MeI is a 
derivative of HIMP, possessing a methyl group on the para position of the benzene ring 
(Fig. 3.1). This modification apparently allows M-MeI to suppress AR protein level as 
well as Akt activation; there is also a noticeable change in M-MeI’s IC50 value between 
regular and SR conditions, indicating its mechanism of growth inhibition includes the 
suppression of AR signaling (Figs. 3.4C-E). Supportively, as shown in Fig. 3.5B, upon 
M-MeI treatment, there is a consistent, progressive decrease in AR protein. This 
coincides with a decrease in PSA, a target of AR, as well as p66Shc protein level, a 
protein regulated by androgens which is involved in cell proliferation and apoptosis (Figs. 
3.4C and 3.4D). Downstream pro-proliferative markers, cyclin D1 and PCNA were also 
down-regulated over-time to a greater extent by M-MeI compared to HIMP. In addition, 
STAT5 signaling is proposed to be involved in the transition from androgen-sensitive to 
CR PCa and activated STAT5 can enhance nuclear translocation of AR [40]. 
Interestingly, as seen in Figs. 3.4C and D, while M-MeI inhibited Stat5 phosphorylation 
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at Y694 in MDA-AI cells, it increased Y694 phosphorylation in LNCaP cells. This 
inconsistent effect suggests inhibition of STAT5 activation is not vital to M-MeI’s 
suppression of PCa. Furthermore, M-MeI strongly inhibited the phosphorylation of pro-
survival protein Akt (Ser473) (Figs. 3.4C-E) as well as induced pro-apoptotic proteins 
p53 and Bax (Fig. 3.5B) [27]. Thus, M-MeI’s anti-tumorigenic effect on PCa is due to its 
strong inhibition of both Akt and AR signaling pathways. 
Unexpectedly, the kinetic analysis revealed an interesting phenomenon: upon 
HIMP and M-MeI treatments over time, both compounds, though to a greater extent by 
M-MeI, decreased the protein level of active unphosphorylated cyclin B1 (Fig. 3.5B, lower 
band) and increased the inactive phosphorylated band (upper band) (Fig. 3. 5B) [41]. 
Cyclin B1, a key regulator of mitosis, is phosphorylated during the G2 phase and 
becomes unphosphorylated upon the cell reaching M phase [41]. To validate further, we 
performed cell cycle analysis on HIMP- and M-MeI-treated cells by flow cytometry. 
Compared to control cells, M-MeI-treated cells had lower percentages of cells in S 
phase, corresponding with a decrease in cell proliferation, and twice the percentage of 
cells in the G2 phase. Minimal changes were observed in HIMP-treated cells, although 
both treatments increased the percentage of cells undergoing apoptosis (Fig. 3.5C). 
Together, this data indicates these imidazopyridine derivatives function to inhibit the 
transition of PCa cells between G2 and M phases, though the exact mechanism remains 
to be elucidated.  
In summary, our data shows imidazopyridine derivatives exhibit inhibitory activity 
of tumorgenicity in CR PCa cells. Each compound displayed differential effects on Akt 
and AR signaling pathways, and further studies are needed to determine the mechanism 
by which these molecules suppress the growth of CR PCa. Among the four compounds 
investigated, M-MeI was found to suppress multiple signaling pathways related to PCa 
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progression, including classical target AR as well as the Akt survival pathway, making it 
a promising candidate for future therapeutic studies. Importantly, this compound displays 
selective growth inhibition, having a significantly greater suppressive effect on PCa 
compared to benign prostate epithelial cells. Thus, M-MeI can serve as a lead 
compound for imidazopyridine side-chain modifications, which could yield more potent, 
selective agents to improve the treatment of CR PCa patients. Future investigation to 
elucidate M-MeI’s specific mechanism of inhibition and in vivo studies will help better 
















Figure 3.1 Structures of imidazopyridine derivatives. HIMP, 3-phenyl-1-(pyridine-












Figure 3.2 Effects of imidazopyridine derivatives on the proliferation of 
prostate epithelial cells.  
(A) Dosage effect of Imidazopyridine derivatives on LNCaP C-81 cells. Cells were 
plated in six-well plates at 2 x 103 cells/cm2 in regular medium and grown for 72 
hours. One set of cells was then fed with fresh regular medium containing 0,1,5, or 
10 µM imidazopyridine derivatives with solvent alone for control and grown for an 
additional 72 hours. Another set of cells was first steroid starved in SR medium for 48 
hours then treated with respective compounds in fresh SR media containing 1 nM 
DHT for 72 hours. All cells were trypsinized and live cell numbers were counted. The 
experiment was conducted in duplicate wells with 3 sets of independent experiments. 
The results presented are mean ± SE; n=2x3. *p<0.05 **p<0.005 ***p<0.0005.  
(B) Effects of statin-agents on the growth of various PCa cells and immortalized 
prostate epithelial cells. All cells were plated in six-well plates at the noted density in 
their respective medium for three days, steroid-starved for two days, then fed with 
fresh SR medium with 1 nM DHT containing 10 µM imidazopyridine derivatives and 
grown for three additional days.  Cells were trypsinized and live cell number was 
counted. LNCaP C-81 - 2 x 103 cells/cm2, MDA PCab2b AI - 3 x 103 cells/cm2, PC-3 - 
2 x 103 cells/cm2, RWPEI – 7.5 x103 cells/cm2. All experiments were performed in 
triplicate wells with 3 sets of independent experiments.  Results presented are mean 










Figure 3.3 Effects of imidazopyridine derivatives on the tumorigenicity of 
LNCaP C-81 cells.  
(A) Clonogenic assay on plastic wares.  LNCaP C-81 cells were plated in six-well 
plates at densities of 20, 200, and 2,000 cells/well. After 24 hours, attached cells 
were treated with respective compounds at 10 µM concentrations of imidazopyridine 
derivatives or solvent alone as control. Cells were fed on days 3, 6, and 9 with fresh 
culture media containing respective inhibitors. On day 10, cells were stained and the 
number of colonies counted. The photos of representative colony plates were taken 
from plates seeded with 2,000cells/well, and the number of colonies shown was 
counted also from plates seeded with 2,000cells/well. Minimal colony formation was 
observed at densities of 20 and 200 cells/well. Results presented are mean ± SE; 
n=2x3. ***p<0.0001.   
(B) Anchorage-independent soft agar assay. LNCaP C-81 cells were plated at a 
density of 5 x 104 cells/35mm dish in 0.25% soft agar plates. The following day, cells 
in doublets or greater were marked and excluded from the study. Media were added 
every three days, and at the end of 5 weeks, colonies formed were stained and 
counted. Representative images of colonies are shown (above) and the colony 
number was counted (below). The experiments were performed in duplicate with 3 
sets of independent experiments. Results presented are mean ± SE; n=2x3. *** 
p<0.0001. 
(C). Cell adhesion assay on plastic wares. Cells were suspended in treatment media 
for 30 minutes before being plated in 6-well plates at 3 x103 cells/cm2 using the same 
treatment media. Cells were allowed to adhere for one hour, fixed and stained by 0.2% 
crystal violet solution (50:50, water:MeOH). The total number of cells in five fields at 
40x magnification for each well was counted. The experiments were performed in 
triplicate with 3 sets of independent experiments. Results presented are mean ± SE; 
n=3x3. *p<0.05; **p<0.01. 
(D). Cell migration transwell assay. Cell migration was assessed via Boyden chamber. 
An aliquot of 5 x 104 C-81 cells was seeded in the insert of 24-well plates in media 
containing 10 µM respective compounds with solvent alone for control in both upper 
and lower chambers. After 24-hour incubation, the migrated cells were stained and 
those cells remaining in the upper chamber were removed via cotton swab. Cells which 
had migrated through to the lower chamber were counted. Representative images are 
shown at 40x magnification. The experiments were performed in triplicate with 3 sets 















Figure 3.4 Effects of imidazopyridine derivatives on PCa proliferative and 
apoptotic signaling under SR conditions. 
(A) LNCaP C-81 cells were plated in triplicate in T25 flasks at 4 x 103 cells/cm2 in 
regular medium, grown for 72 hours then steroid starved for 48 hours. Cells were 
then treated with 10 µM imidazopyridine derivatives or DMSO as control for an 
additional 72 hours under SR conditions. Cells were trypsinized and live cell numbers 
counted via Trypan Blue assay. The experiments were performed in triplicate with 3 
sets of independent experiments. *** p<0.0005.  
(B) MDA PCa2b-AI cells were grown, treated, and counted under conditions as 
described above in (A) for LNCaP C-81 cells. Results presented are mean ± SE; 
n=3x3. *p<0.05; **p<0.005; ***p<0.0005. 
(C) LNCaP C-81 total cell lysate proteins were collected from (A) after cell number 
counting. Those cells were grown in SR conditions and analyzed for phosphorylated 
Akt and STAT5, as well as total AR, Akt, Shc, p53, cyclin B1, cyclin D1, PCNA, BclXL, 
and Survivin protein levels. β-actin protein level was used as a loading control.  
Similar results were observed in two sets of independent experiments.  
(D) MDA PCa2b-AI total cell lysate proteins from (B) after cell number counting. Cells 
were grown in SR conditions and analyzed for phosphorylated STAT5, as well as 
total AR, Shc, p53, cyclin B1, cyclin D1, PCNA, BclXL, and Survivin protein levels. β-
actin protein level was used as a loading control. Similar results were observed in 
three sets of independent experiments. 
(E) MDA PCa2b-AI total cell lysate proteins from cells grown in regular conditions 
were analyzed for phosphorylated Akt and total Akt. β-actin protein level was used as 












Figure 3.5 Kinetic analysis of HIMP and M-MeI’s effects on LNCaP C-81 cells 
under steroid-deprived conditions. 
(A) Cells were plated in six-well plates at 2 x 103 cells/cm2 in regular medium for 
three days, then steroid-starved for 48 hours followed by treatment with 10 µM HIMP 
or M-MeI in SR medium containing 1 nM DHT. Solvent alone was used for controls. 
On day 0, 1, 3, 5 and 7, one set of cells in duplicates from each group was harvested 
for live cell counting. Remaining cells were replenished with fresh respective 
medium. The experiments were performed in duplicates with 3 sets of independent 
experiments. Results presented are mean ± SE; n=2x3. *p<0.05; **p<0.005; 
***p<0.0005. 
(B) Total cell lysate proteins from HIMP- and M-MeI-treated C-81 cells from (A) were 
collected and analyzed for AR, cPSA, cyclin B1, PCNA, Bax, p53, and Bcl-XL 
proteins. β-actin protein level was used as a loading control.  
(C) Histograms of cell cycle distributions of LNCaP C-81 cells upon 7 days of HIMP 
and M-MeI treatments. Cells were plated in T25 flasks at 2 x 103 cells/cm2 in regular 
medium for three days, then steroid-starved for 48 hours followed by treatment with 
10 µM HIMP or M-MeI in SR medium with 1 nM DHT and solvent DMSO alone as 
control. One set of cells from each group was harvested after 3, 5, and 7 days 
treatment for flow cytometric analysis. Similar results were obtained from two sets of 











Figure 3.6 Histograms of cell cycle distributions of LNCaP C-81 cells upon 3 
and 5 days of HIMP and M-MeI treatments. Cells were plated in T25 flasks at 2 x 
103 cells/cm2 in regular medium for three days, then steroid-starved for 48 hours 
followed by treatment with 10 µM HIMP or M-MeI in SR medium with 1 nM DHT and 
solvent DMSO alone as control. One set of cells from each group was harvested 
after 3, 5, and 7 days treatment for flow cytometric analysis. Similar results were 
obtained from two sets of independent experiments. The data shown were 






1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA. Cancer J. Clin. 64: 9-29. 
2. Smalet O, Scher HI, Small EJ, Verbel D A, McMillan A, Regan K, Kelly W K, Kattan M 
(2002) Nomogram for overall survival of patients with progressive metastatic 
prostate cancer after castration. J. Clin. Oncol. 20: 3972-3982. 
3. Asmane I, Céraline J, Duclos B, Rob L, Litique V, Barthélémy P, et al. (2011) New 
strategies for medical management of castration-resistant prostate cancer. 
Oncology 80: 1-11. 
4.  Saad F, Hotte SJ (2010) Guidelines for the management of castrate-resistant 
prostate cancer. Can. Urol. Assoc. J. 4: 380-384. 
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008)  
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced 
prostate cancer: updated survival in the TAX 327 study. J. of Clin. Oncol. 20: 
242–245. 
6.  De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. (2010)  
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant 
prostate cancer progressing after docetaxel treatment: a randomised open-label 
trial. Lancet 376: 1147–1154.  
7.  De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et. al. (2011)  
Abiraterone and increased survival in metastatic prostate cancer. New Eng. J. of 
Med. 364: 1995-2005. 
8.  Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. (2012) 
Increased survival with enzalutamide in prostate cancer after chemotherapy. 
New Eng. J. of Med. 367: 1187–1197. 
78 
 
9.  Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. (2012) 
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Eng. 
J. of Med. 363: 411–422. 
10.  Parker C, Heinrich D, O’Sullivan J M, Fossa SD, Chodacki A, Demkow T, et al. 
(2012)  Overall survival benefit and safety profile of radium-223 chloride, a first-
in-class alpha-pharmaceutical: results from a phase III randomized trial 
(ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with 
bone metastases. J. Clin. Oncol. 30: abstract 8. 
11. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. (2013) 
Castration-Resistant Prostate Cancer: AUA Guideline. J. Urol. 190: 429-438. 
12. Hong SK, Kim JH, Lin MF, Park JI (2011) The Raf/MEK/extracellular signal-regulated 
kinase ½ pathway can mediate growth inhibitory and differentiation signaling via 
androgen receptor downregulation in prostate cancer cells. Exp. Cell Research 
317: 2671-2682. 
13. Lin HK, Yeh S, Kang HY, Chang C (2001) Akt suppresses the androgen-induced 
apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 98: 1200-
7205. 
14. Bitting RL, Armstrong AJ (2013) Targeting the PI3K/Akt/mTOR pathway in 
castration-resistant prostate cancer. Endocrine-Related Cancer 20: 83-99. 
15. Rhodes N, Heerding DA, Duckett DR , Eberwein DJ, Knick VB, Langsing TJ, et.al. 
(2008) Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic 
and Antitumor Activity. Cancer Res 68: 2366-2374. 
79 
 
16.  Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, et al. (2012) 
Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent 
ASK1 inhibitors. Bioorg. Med. Chem. Lett. 22: 7326-7329. 
17.  Newhouse BJ, Wenglowsky S, Grina J, Laird ER, Voegtli WC, Ren L, et al. (2013) 
Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett. 23: 
5896-5899. 
18. Muniyan S, Chou YW, Ingersoll MA, Devine A, Morris M, Odero-Marah VA, et al. 
(2014) Antiproliferative activity of novel imidazopyridine derivatives on castration-
resistant human prostate cancer cells. Cancer Lett. 353: 56-67. 
19. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF (1998) Expression of 
human prostatic acid phosphatase correlates with androgen-stimulated cell 
proliferation in prostate cancer cell lines. J. Biol. Chem. 273: 5939-5947. 
20. Meng TC, Lee MS, Lin MF (2000) Interaction between protein tyrosine phosphatase 
and protein tyrosine kinase is involved in androgen-promoted growth of human 
prostate cancer cells. Oncogene 19: 2664-2677. 
21. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF (2002) Establishment and 
characterization of androgen-independent human prostate cancer LNCaP cell 
model. Prostate 50: 222-235. 
22. Dillard PR, Lin MF, Khan SA (2008) Androgen-independent prostate cancer cells 
acquire the complete steroidogenic potential of synthesizing testosterone from 
cholesterol. Mol. Cell. Endocrinol. 295: 115-120. 
23. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, et al. (2001) 
Decreased expression of cellular prostatic acid phosphatase increases 
tumorigenicity of human prostate cancer cells. J. Urol. 166: 1943-1950. 
80 
 
24. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. Prostate. (2011) 
PC3 is a cell line characteristic of prostatic small cell carcinoma. 15:1668-79. 
25. Wang J, Dyers L Jr, Mason R Jr, Amoyaw P, Bu XR (2005) Highly efficient and direct 
heterocyclization of dipyridyl ketone to N,N-bidentate ligands. J. Org. Chem. 70: 
2353-2356. 
26. Chen SJ, Karan D, Johansson SL, Lin FF, Zeckser J, Singh AP, et al. (2007) 
Prostate-derived factor as a paracrine and autocrine factor for the proliferation of 
androgen receptor-positive human prostate cancer cells. Prostate 67: 557-571. 
27. Chuang TD, Chen SJ, Lin FF, Veeramani S, Kumar S, Batra SK, et al. (2010) 
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, 
dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. 
Chem. 285: 23598-23606.  
28. Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D, Wang J, at al. (2011) 
Histone deacetylase inhibitor valproic acid suppresses the growth and increases 
the androgen responsiveness of prostate cancer cells. Cancer Lett. 311: 177-86. 
29. Telford WG, King LE, Fraker PJ, Evaluation of glucocorticoid-induced DNA 
fragmentation in mouse thymocytes by flow cytometry. Cell Prolif. 25 (1991) 447-
459. 
30. Meng TC, Lin MF (1998) Tyrosine phosphorylation of c-ErbB-2 is regulated by the 
cellular form of prostatic acid phosphatase in human prostate cancer cells. J. 
Biol. Chem. 273: 22096-22104. 
31. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate 
cancer. Nat. Rev. Cancer 1: 34-45. 
81 
 
32. Tilley WD, Wilson CM, Marcelli M, McPaul MJ (1990) Androgen receptor gene 
expression in human prostate carcinoma cell lines. Cancer Res. 50: 5382-6. 
33. Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF, et al. (2004) p66Shc 
protein is upregulated by steroid hormones in hormone-sensitive cancer cells and 
in primary prostate carcinomas. Int. J. Cancer 108: 672-678. 
34. Veeramani S, Igawa T, Yuanv TC, Lin FF, Lee M S, Lin JS, et al. (2005) Expression 
of p66(Shc) protein correlates with proliferation of human prostate cancer cells. 
Oncogene 24: 7203-7212. 
35. Kumar S, Rajendran M, Alam SM, Lin F F, Cheng PW, Lin MF (2011) Steroids up-
regulate p66Shc longevity protein in growth regulation by inhibiting its 
ubiquitination. PLoS One 6: e15942. 
36. Rajendran M, Thomes P, Zhang L, Veeramani S, Lin MF (2010) p66Shc-a longevity 
redox protein in human prostate cancer progression and metastasis: p66Shc in 
cancer progression and metastasis. Cancer Metastasis Rev. 29: 207-222. 
37. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, et. al. (2008) 
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer 
cells. Cancer Res. 68: 236-248. 
38. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT (2008) Transcription 
factor signal transducer and activator of transcription 5 promotes growth of 
human prostate cancer cells in vivo. Clin Cancer Res. 14: 1317-24. 
39. Raffo AJ, Perlman H, Chen MW, Day ML, Streitmanv J , Buttyan R (1995) 
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and 
confers resistance to androgen depletion in vivo. Cancer Res. 55: 4438-4445. 
82 
 
40. Oltvai ZN, Milliman  L, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-
619. 
41. Allan LA, Clark PR (2007) Phosphorylation of Caspase-9 by CDK1/Cyclin B1 
Protects Mitotic Cells Against Apoptosis. Molec. Cell. 26: 301-310. 
42. Debes JD, Tindall DJ (2004) Mechanisms of androgen refractory prostate cancer. N. 
Engl. J. Med. 351: 1488-1490. 
43. Knudsen KE, Penning TM. Trends Endocrinol Metab. (2010) Partners in crime: 
deregulation of AR activity and androgen synthesis in prostate cancer. Trends 
Endocinol. Metab. 5:315-24. 
44. Lorente D, Mateo J, Zafeiriou Z, Smith AD, Sandhu S, Ferraldeschi R, de Bono JS. 
(2015) Switching and withdrawing hormonal agents for castration-resistant 
prostate cancer. Nat Rev Urol. 2:37-47. 
45. Heemers HV, Mohler JL. Am J Clin Exp Urol. (2014) Revisiting nomenclature for the 
description of prostate cancer androgen-responsiveness. Am J Clin Exp Urol 
2:121-6. 
46. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, 
Greene GL, Shen Y, Sawyers CL. (2013) Overcoming mutation-based resistance 
to antiandrogens with rational drug design. Elife Epub. 
47. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-
independent prostate cancer. Clin. Cancer Res. 12: 1665-1671. 
48. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. 
vTransatlantic Prostate Group, Molecular characterisation of ERG, ETV1 and 
83 
 
PTEN gene loci identifies patients at low and high risk of death from prostate 
cancer. Br. J. Cancer 102: 678-684. 
49. Taylor BS, Schultz, Hieronymus H, Gopalan, Xiao Y, Carver BS, et al. (2010) 
Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22. 
50. Debes JD, Tindall DJ, Mechanisms of androgen refractory prostate cancer. N. Engl. 
J. Med. 351 (2004) 1488-1490. 
51. Festuccia C, Gravina GL, Muzi P, Pomante R, Venture L, Vessela RL, et. al (2007) 
Bicalutamide increases phosphor-Akt levels through Her2 in patients with 
prostate cancer. Endo-Related Cancer. 14: 601-11. 
52. Hour TC, Chung SD, Kang W Y, Lin YC, Chuang SJ, Huang AM, et. al (2014) EGFR 
mediates docetaxel resistance in human castration-resistant prostate cancer 
through the Akt-dependent expression of ABCB1 (MDR1). Mol. Tox. Epub. 
53. Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, et al. (2012) HS- -116, a 
novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses 
angiogenesis of hepatocellular carcinoma through inhibition of the 
PI3K/AKT/mTOR pathway. Cancer Lett. 316: 187-195. 
54. Lee H, Jung KH, Jeong Y, Hong S, Hong SS (2013) HS-173, a novel 
phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through 
promoting apoptosis and inhibiting angiogenesis. Cancer Lett. 328: 152-9. 
55. Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, et al. (2012) A novel 
imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against 













Statin Derivatives as Therapeutic Agents for Castration-Resistant Prostate Cancer 
 
This chapter is derived from:  
Ingersoll MA, Miller DR, Martinez O, Wakefield CB, Hsieh KC, Simha MV, Kao CL, Chen 
HT, Batra SK, Lin MF (2016) Statin Derivatives as Therapeutic Agents for Castration-










Despite recent advances in modern medicine, castration-resistant prostate 
cancer remains an incurable disease. Subpopulations of prostate cancer cells develop 
castration-resistance by obtaining the complete steroidogenic ability to synthesize 
androgens from cholesterol. Statin derivatives, such as simvastatin, inhibit cholesterol 
biosynthesis and may reduce prostate cancer incidence as well as progression to 
advanced, metastatic phenotype. In this study, we demonstrate novel simvastatin-
related molecules SVA, AM1, and AM2 suppress the tumorigenicity of prostate cancer 
cell lines including androgen receptor-positive LNCaP C-81 and VCaP as well as 
androgen receptor-negative PC-3 and DU145. This is achieved through inhibition of cell 
proliferation, colony formation, and migration as well as induction of S-phase cell-cycle 
arrest and apoptosis. While the compounds effectively block androgen receptor 
signaling, their mechanism of inhibition also includes suppression of the AKT pathway, in 
part, through disruption of the plasma membrane. SVA also possess an added effect on 
cell growth inhibition when combined with docetaxel. In summary, of the compounds 
studied, SVA is the most potent inhibitor of prostate cancer cell tumorigenicity, 
demonstrating its potential as a promising therapeutic agent for castration-resistant 
prostate cancer. 
4.2 Background and Rationale 
Prostate cancer (PCa) is the most frequently diagnosed tumor and second 
leading cause of cancer-related fatality among United States men [1]. The majority of 
prostate tumors are reliant on androgen signaling for their development and progression, 
thus ADT is an effective means of treatment and remains the current standard-of-care 
therapy for metastatic PCa [2,3]. However, most patients ultimately relapse: cancer cells 
are able to endure the androgen-depleted environment and develop CR tumors for 
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which the median life-expectancy is less than 19 months. Despite advancements in post-
ADT therapy, CR PCa remains an incurable disease maintaining an immediate need for 
advancement in treatment strategies [4,5]. 
Though CR tumors are no longer responsive to ADT, the majority continue to rely 
on AR signaling for growth and progression [3,6-8]. While the mechanism through which 
tumor cells acquire castration-resistance may vary, one mechanism is the development 
of intracrine regulation by activating the androgen biosynthesis pathway. [6,7,9,10]. For 
example, AR-positive LNCaP C-81 cells acquire the complete steroidogenic ability to 
synthesize androgens from cholesterol and obtain the CR phenotype [11]. This suggests 
inhibitors of steroid biosynthesis such as statins, which suppress cholesterol production 
via inhibition of HMG-CoA reductase, can be effective therapeutic agents for this 
population of tumors [12]. Supportively, ADT combined with simvastatin, a statin 
compound, reduces tumor growth and delays CR progression in murine models [13]. 
Moreover, epidemiological studies have reported a significant correlation between statin 
use and overall reduced risk of PCa diagnosis in addition to decreased development of 
aggressive, metastatic phenotype. [14]. Meta-analyses of observational studies have 
found ADT and/or radiotherapy combined with statin treatment resulted in a higher 
recurrence-free survival rate [15,16]. Together, these findings support the usage of 
statins to treat CR PCa patients. Importantly, FDA-approved cholesterol lowering drugs, 
such as simvastatin, possess well tolerated side-effect profiles [17]. This makes statins 
an ideal treatment option and suggests they can be combined with existing 
chemotherapeutic agents with minimal additional risk to the patient. 
Currently, the mechanism of statin-mediated inhibition of PCa tumorigenicity 
remains poorly understood; further investigation using clinically-relevant cell line models 
is required. Moreover, PCa research on statins is frequently conducted using 
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concentrations well-exceeding what is clinically relevant to achieve significant data, 
indicating a need for more potent statin derivatives [18]. In this study, we investigate the 
efficacy of novel statin derivatives SVA, AM1, and AM2 (Fig. 4.1) as therapeutic agents 
for CR PCa with the goal of producing a more potent compound to effectively treat CR 
PCa. SVA is a potent metabolite of simvastatin, while AM1 and AM2 are amide modified 
statin derivatives with lower HMG-CoA reductase inhibition [19]. In addition, we use 
LNCaP C-81 cells as our primary cell model because they are a useful representative of 
advanced CR PCa: they express functional AR as well as readily proliferate and secrete 
PSA under SR conditions which strongly correlates with clinical CR PCa phenotype [20-
22]. Furthermore, C-81 cells exhibit intracrine growth regulation in which the cells 
possess the ability to synthesize androgens from cholesterol [11]. This acquired 
steroidogenic ability provides a mechanism of escape from ADT and development of 
castration-resistance. In this study, we demonstrate for the first time that the novel statin 
compound SVA is a potent inhibitor of CR PCa cells and investigate its mechanism of 
tumor suppression using clinically relevant cell line models. 
4.3 Results 
4.3.A Growth Suppressive Effects of Statin Derivatives on PCa Cells 
Many reports analyzing the effect of statin agents on CR PCa cells have been 
carried out using AR-null PCa cells lines such as PC-3 or DU145 [34]. However, most 
clinical CR PCa retains AR signaling; therefore in this study we used the LNCaP C-81 
cell line which possesses active AR and is a more clinically useful model for CR PCa. C-
81 cells were initially treated with simvastatin (Fig. 4.2A) or atorvastatin (data not shown) 
at concentrations from 0-20 µM under regular culture conditions. After 3 days of 
treatment, cell growth suppression was determined by live-cell counting, and both 
compounds were found to have similar potency with an IC50 of 8.3 µM (Fig. 4. 2A). 
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Western blot analysis showed a similar dosage-response of PCNA protein level, a cell 
proliferation marker (Fig. 4.2B). Inhibition of cell growth by simvastatin was observed at 
clinically achievable micromolar concentrations. 
In attempt to identify more potent statin derivatives, LNCaP C-81 cells were 
treated for three days in regular culture medium containing 20 µM of each compound: 
simvastatin, SVA, AM1, and AM2. Simvastatin and SVA inhibited C-81 cell growth by 
over 80%, while AM1 and AM2 suppressed growth by 20% and 50%, respectively (Fig. 
4.2C). Interestingly, when C-81 cells were treated in SR medium to mimic ADT 
conditions, the potency of simvastatin decreased with 60% inhibition, while that of SVA, 
AM1, and AM2 remained unchanged (Fig. 4.2C). Thus, a concentration of 20 µM was 
found to be suitable for treatment under SR conditions used to conduct all further 
experiments. 
The inhibitors were then tested on a panel of PCa cell lines under SR conditions 
including: VCaP, PC-3, and DU145 (Fig. 4.2D-F). SVA was the most effective, 
suppressing androgen-sensitive VCaP cell growth by 80%, followed by simvastatin at 
40%, while AM1 and AM2 each had 20% growth inhibition (Fig. 4.2D) [25]. In DU145 
and PC-3 cell lines, both of which are androgen-independent and lack AR expression, 
SVA was the most potent, followed by simvastatin, and AM1 and AM2 exhibited the least 
inhibitory effect on both cell lines (Fig. 4.2E-F). Then, to determine compound selectivity, 
the experiment was repeated using the immortalized benign prostate epithelial RWPE-1 
cell line. All compounds were found to be less potent against RWPE-1 cells with SVA 
demonstrating the most selectivity (Fig. 4.2G). Together, the data demonstrates that 
SVA is the most potent and selective suppressor of both androgen-sensitive and 




4.3.B Effects of Statin Derivatives on PCa Cell Tumorigenicity 
Using the LNCaP C-81 cell line as a model system, we investigated whether 
statin derivatives can suppress PCa tumorigenicity including cell colony formation and 
migration. In the clonogenic anchorage-dependent assay, LNCaP C-81 cells were 
treated with each compound at 20 µM for 10 days. As shown in Figure 4.3A, both 
simvastatin and SVA were potent inhibitors of colony growth on the plastic-ware surface 
with over 90% inhibition. Compounds AM1 and AM2 were less potent with about 20% 
and 55% inhibition, respectively. Colony formation in a 3-dimentional environment was 
evaluated using the soft agar anchorage-independent assay, in which LNCaP C-81 cells 
were cultured in an agarose matrix for six weeks. As seen in Figure 4.3B, SVA 
suppressed colony formation by 90%, while simvastatin reduced colony growth by 60%. 
AM1 and AM2 each reduced colony growth by 40%. The colony size was also 
decreased by SVA and simvastatin. 
The Boyden Chamber transwell migration assay was used to investigate the 
effect of these compounds on PCa cell migratory potential. SVA inhibited migration by 
over 90%, closely followed by simvastatin at 80%. AM1 and AM2 had similar effects with 
40% and 45% inhibition, respectively (Fig. 4.3C). Collectively, compound SVA exhibited 
the most potent inhibitory activity on PCa cell tumorigenicity. 
4.3.C Suppression of Cholesterol Synthesis by Statin Derivatives 
Clinically, statin derivatives, such as simvastatin, are primarily prescribed to 
reduce patients’ circulating cholesterol levels. To examine their ability to reduce 
cholesterol in PCa cells, statin compound-treated LNCaP C-81 cells were stained with 
Filipin III for cholesterol detection and the fluorescence was semi-quantified via confocal 
microscopy. As shown in Figure 4.4A, while all compounds significantly reduced cellular 
cholesterol levels, SVA was the most effective with a 50% reduction of cholesterol level 
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in treated cells. Unexpectedly, simvastatin and AM1 had a similar 35% reduction in 
cholesterol level, while AM2 was least effective with only 20% inhibition. 
4.3.D Influence of Statin Derivatives on PCa Cell Membrane Integrity 
Cholesterol is an integral component of cell membrane stability and fluidity and is 
highly enriched in lipid rafts which anchor many proteins vital to cell signaling. Therefore, 
decreased cholesterol levels are expected to destabilize the cell membrane and alter cell 
signaling. We determined the impact of these compounds on membrane integrity by 
Trypan Blue dye-exclusion assay. As shown in Figure 4B, SVA induced membrane 
damage in 30% of treated cells and simvastatin disrupted membranes in 12% of cells, 
while compounds AM1 and AM2 had no significant impact on membrane permeability. 
The data together indicates these compounds suppress tumor cells, in part, by reducing 
cholesterol levels (Fig. 4.4A) and disrupting cell membranes (Fig. 4.4B). 
4.3.E SVA Inhibition of Androgen Receptor 
Due to the importance of AR function in CR PCa, the effect of SVA on AR was 
evaluated in LNCaP C-81 cells. Cells were grown in SR medium with or without 10 nM 
DHT, treated with SVA for 3 days, and whole cell lysates were analyzed via western blot. 
As shown in Figure 4.4C, under androgen-deprived conditions, SVA functioned as a 
potent suppressor of AR protein level. However, in the presence of 10 nM DHT, AR was 
partially protected from SVA blockage. SVA strongly reduced growth-regulator Cyclin B1 
protein, independent of the presence of androgens [29]. In parallel, cell growth was 
greatly suppressed by SVA regardless of the presence of androgens and correlates with 
Cyclin B1 protein levels (Fig. 4.4D). Thus, SVA effectively inhibits Cyclin B1, a positive 




4.3.F Effect of Statin Derivatives on PCa Cell Cycle 
To further investigate the mechanism through which statin derivatives inhibit PCa 
cell tumorigenicity, we focused our efforts on comparing SVA and AM1 with simvastatin 
and performed cell cycle analysis on statin-treated LNCaP C-81 cells. Flow cytometry 
analysis (Fig. 4.4E) revealed the percentage of apoptotic cells rose sharply under SVA 
and simvastatin treatments to 66% and 27%, respectively, compared to that of only 2% 
of control and 4% of AM1-treated cells. In addition, SVA and simvastatin treatments 
greatly increased the percentage of cells in S phase accompanied with a decreased 
percentage of cells in G2 phase. Thus, SVA and simvastatin induce apoptosis as well as 
cell cycle arrest in S phase. 
4.3.G Effect of Statin Derivatives on Cell Signaling Under SR Conditions 
To investigate the mechanism through which the statin derivatives inhibit PCa 
tumorigenicity under SR conditions, we analyzed their effects on key signaling molecules 
known to contribute to PCa progression using LNCaP C-81 cells. AR is a major target of 
anti-PCa agents and remains a vital signaling pathway even in CR PCa cells [27,28]. 
While all compounds decreased AR protein in C-81 cells, SVA was the most potent 
followed by simvastatin, and AM1 had only marginal effect (Fig. 4.5A). This correlates 
with reduced cellular prostate-specific antigen (cPSA) with the exception of AM1 
treatment. Interestingly, secreted prostate specific antigen (sPSA) protein level was 
increased by simvastatin and SVA. In addition, ErbB-2 is a transmembrane tyrosine 
kinase which regulates AKT and can be activated by androgen signaling in PCa through 
phosphorylation at Y1221/2 [20-22,30]. Upon treatment with statin derivatives, all agents 
reduced ErbB-2 Y1221/2 phosphorylation with SVA having the greatest effect. SVA also 
reduced the total ErbB-2 protein while other compounds had a limited impact (Fig. 4.5A). 
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Furthermore, while all statin derivatives inhibited AKT phosphorylation at S473, SVA 
also effectively reduced total AKT protein levels. 
Downstream targets of AKT include Survivin and p53, while both AKT and AR 
can regulate Cyclin B1 [33,35].  AKT upregulates Survivin, an anti-apoptotic protein, and 
upon treatment, all compounds greatly reduced Survivin protein levels (Fig. 4.5A). Cyclin 
B1, a cell growth regulator, was strongly inhibited by simvastatin and SVA, but not AM1. 
Furthermore, p53 is an inducer of apoptosis and is suppressed by AKT; p53 was 
elevated upon statin compound treatment and its downstream target BAX, another pro-
apoptotic protein [36], was elevated only by SVA. Conversely, anti-apoptotic Bcl-xL 
protein levels were greatly reduced by all statin compounds (Fig. 4.5A). Elevated levels 
of cleaved PARP and Caspase 3 were also observed in treated cells with SVA having 
the greatest effect, providing further evidence of induced apoptosis. Together, upon 
statin compound treatment there is an overall trend of proliferative and anti-apoptotic 
protein inhibition, while pro-apoptotic proteins were induced. 
We investigated whether oxidative stress is involved in statin-induced tumor 
suppression. Indeed, as shown in Figure 4.5A, NOX5 protein, which functions to 
generate superoxide at the cell membrane, was greatly increased by SVA treatment. 
Moreover, while no observable change was found in redox-sensitive NF-ĸB protein, 
ROS-response protein Nrf2 and its downstream target HO-1 were highly induced by 
SVA and to a lesser extent by simvastatin. This may indicate simvastatin and SVA 
promote oxidative stress resulting in activation of apoptotic pathways.  
Statin derivatives also inhibit PCa cell migration (Fig. 4.3C). Since AKT is 
associated with motility, we analyzed the level of Snail protein, a downstream target of 
AKT, as well as activation of p38, both of which are associated with cell migration and 
stress-response [37,38]. Snail was suppressed by both simvastatin and SVA and 
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correlated with inhibition of AKT activation. Phosphorylation and activation of p38 was 
inhibited by SVA and AM1, but not by simvastatin (Fig. 4.5A). 
To further validate the compounds’ effect on PCa signaling, primary target 
molecules were also investigated using VCaP cells shown in Figure 4.5B. A similar trend 
in AR, cPSA, Cyclin B1, Survivin, PARP, Caspase 3, Nrf2, and HO-1 protein levels were 
observed compared to C-81 treated cells with SVA having the greatest suppressive 
effect. Interestingly, simvastatin had greater inhibitory effect on total and phosphorylated 
ErbB-2 than SVA. In addition, while SVA was again the most potent inhibitor of total and 
phosphorylated AKT, AM1 had a greater inhibitory effect than simvastatin. Overall, a 
similar trend in inhibition of key functional proteins was observed in both VCaP and 
LNCaP C-81 cell lines. 
4.3.H DCF-DA Dye Analysis of LNCaP C-81 Cells Treated with Statin Derivatives 
Upon observing an increase of NOX5 protein level as well as ROS-response 
proteins Nrf2 and HO-1 in statin-treated LNCaP C-81 cells, we investigated the effect of 
these compounds on ROS generation. This was semi-quantified by DCF-DA dye and 
fluorescence was measured via flow cytometry. As shown in Figure 4.5C, both 
simvastatin and SVA significantly increased cellular levels of ROS, while AM1 had no 
significant effect. This data demonstrates simvastatin and SVA induce ROS generation, 
causing oxidative stress in PCa cells under SR conditions which can contribute to growth 
suppression and apoptosis. 
4.3.I LNCaP C-81 Migration in the Presence of Small Molecule Inhibitors 
Statin compounds inhibit PCa cell migration (Fig. 4.3C) as well as AKT and p38 
pathways (Fig. 4.5A) which are both associated with cell motility. To determine which of 
these signaling pathways regulate LNCaP C-81 cell migration, transwell assays were 
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conducted with small molecule inhibitors of p38 (SB202190), AKT (MK-2206), and ErbB-
2 (AG879) [39-41]. As shown in Figure 4.5D, inhibition of p38 had no impact on C-81 cell 
migration; inhibition of ErbB-2 reduced migration by 50%, and inhibition of AKT 
suppressed migration by over 80%. The results indicate statin compounds inhibit of PCa 
cell migration primarily through suppression of the ErbB-2/AKT signaling pathway. 
4.3.J Growth Suppression via Combined Docetaxel and Statin-Derivative 
Treatment 
 Simvastatin has previously been reported to have an added inhibitory effect on 
PCa cell growth when combined with docetaxel treatment [42]. To determine the 
interaction between SVA and docetaxel, the compounds were used to treat C-81 cells 
under SR conditions independently and in combination, and cell growth was determined. 
Both simvastatin and SVA (5 µM each) were found to possess an added effect on cell 
growth suppression when combined with docetaxel (1 nM) (Fig. 4.6). 
4.4 Discussion 
CR PCa remains an incurable disease and an effective therapy is immediately 
needed. Recent in vitro and epidemiological studies revealed that inhibition of 
cholesterol synthesis by statin derivatives may be an effective treatment strategy for CR 
PCa [11-16,43]. In the present study utilizing clinically-relevant PCa cell line models, we 
show for the first time that novel statin derivatives are effective suppressors of CR PCa 
tumorigenicity through inhibition of both AR and AKT pathways as well as induction of 
apoptosis. These compounds have the potential to serve as effective therapeutic agents 
for CR PCa. 
In addition to template-compound simvastatin, we investigated the ability of novel 
statin derivatives SVA, AM1, and AM2 to suppress CR PCa proliferation. We chose 
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LNCaP C-81 cells as our primary experimental model due to their steroidogenic ability to 
synthesize androgens from cholesterol in addition to the possession of many 
biochemical properties common to clinical CR PCa [11,20-22]. While simvastatin is a 
less potent inhibitor of C-81 cell proliferation under SR conditions compared to regular 
steroid conditions, the potency of SVA, AM1, and AM2 remains unaltered. This may 
indicate steroid-deprivation reduces the cells’ ability to activate simvastatin, while SVA, 
AM1, and AM2 are in active states. Moreover, SVA is the most potent inhibitor of cell 
growth in all cell lines examined. Notably, the compounds are effective inhibitors of AR-
negative DU145 and PC-3 cell growth, which indicates statin derivatives suppress cell 
proliferation through alternative mechanisms in addition to inhibition of AR signaling. The 
compounds were also found to have selective inhibition, with all compounds 
demonstrating reduced potency against benign epithelial RWPE-1 cells as shown in 
Figure 4.2G. Furthermore, these compounds suppress tumorigenicity including colony 
formation and migration. Among them, SVA exhibits the most potent suppression of PCa 
tumor phenotype followed by simvastatin, while AM1 and AM2 had the least effect.  
We determined whether these compounds have an impact on AR signaling to 
test our hypothesis that depriving C-81 cells of cholesterol blocks their ability to 
synthesize androgen and thus inhibits AR pathways. Statin derivatives were found to 
reduce AR protein level correlating with a decrease in cellular PSA, despite an increase 
in secreted PSA. This rise in secreted PSA may be attributed to the loss of membrane 
stability, allowing PSA protein to leak out of the cell. Moreover, SVA is a potent inhibitor 
of AR in C-81 cells under SR conditions; however, in the presence of DHT, the impact 
on AR protein level is reduced (Fig. 4.4C). Unexpectedly, SVA suppression of cell 
proliferation is only marginally reduced in the presence of androgens, while its impact on 
AR protein level is greatly diminished (Figs. 4.2C, 4.4D). This data correlates with 
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observed statin inhibition of AR-null PC-3 and DU145 proliferation (Figs. 4.2E-F) and 
thus supports the notion that cell growth is suppressed by other mechanisms in addition 
to AR signaling. 
PCa cells possess enriched cholesterol and lipid raft concentrations in 
comparison to benign cells, and simvastatin has been reported to reduce both lipid raft 
and cell cholesterol levels in prostate cells [43,44]. The observations in those reports 
correlate with our data showing a reduction in cellular cholesterol and destabilization of 
C-81 cell membranes upon statin compound treatment (Fig. 4.4A, 4.4B). Additionally, 
the compounds’ selective growth inhibition may be attributed to the fact that PCa cells 
undergo rapid proliferation and more dynamic membrane activity compared to benign 
cells. Moreover, Adam et al. [45] demonstrated that a cholesterol-sensitive subgroup of 
AKT, which enhances tumor cell survival and metastatic ability, is enriched in PCa cells 
and is dependent upon lipid raft availability for activation via phosphorylation. In parallel, 
a correlation has been reported between decreased AKT activation and prevention of 
lipid raft formation as a result of simvastatin’s inhibition of cholesterol synthesis [44]. 
Indeed, our data clearly demonstrates AKT activation is inhibited by statin compounds 
(Fig. 4.5A, 4.5B) and correlates with loss of membrane integrity (Fig. 4.4B). Collectively, 
inhibition of AKT signaling is a major mechanism of statin-mediated suppression of PCa 
cell tumorigenicity. 
Inhibition of AKT may be achieved via suppression of ErbB-2, a hyper-
phosphorylated and activated transmembrane tyrosine kinase in CR PCa cells which 
can upregulate AKT by promoting activation via S473 phosphorylation [30, 32]. 
Emerging studies reveal, in addition to AR, AKT signaling is vital to the progression and 
development of CR PCa [46,47].  Our data shows statin derivatives inhibit AKT 
activation as well as reduces total AKT protein levels, correlating with ErbB-2 status and 
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their effect on tumor phenotype (Fig 4.5A, 4.5B). We propose disruption of the cell 
membrane can reduce ErbB-2 stability resulting in prevention of AKT activation. 
Alternatively, we cannot rule-out the possibility that statin-agents directly interact with 
and inhibit ErbB-2 and/or AKT. These changes in signaling correlate with a large 
increase of apoptosis and induction of S-phase cell cycle arrest (Fig. 4.4E). Together, 
the data indicates statin compounds suppress cell survival signaling and induce cell 
death while SVA has the most potent effect. 
Upon observing an elevation of pro-apoptotic proteins and a decrease in survival-
associated proteins after statin treatment, we investigated the impact of statin 
compounds on cellular ROS production and induction of oxidative stress. In Figure 4.5C, 
a significant increase in cellular ROS is shown in cells treated with simvastatin and SVA. 
Superoxide generating protein, NOX5, was found to be increased upon treatment with 
statin derivatives, which may contribute to the elevated ROS level. However further 
investigation is required to determine the exact mechanism of its involvement [48]. We 
also observed a rise in ROS-response proteins Nrf2 and its downstream target HO-1 
which induces antioxidant mechanisms within the cell (Fig. 4.5A, 4.5B) [49]. While the 
total protein levels of NFĸB, another ROS-sensitive protein, were not altered upon statin-
compound treatment, changes in its subcellular localization may occur and requires 
further study. Collectively, our data shows statin derivatives induce cellular stress in part 
by increasing ROS which correlates with elevated apoptosis. 
In addition to inhibition of proliferation and induction of apoptosis, statin 
derivatives also reduce cell migratory ability (Fig. 4.3C). Western blot analysis (Fig. 
4.5A) revealed the inhibition of a number of motility-related proteins. Moreover, AKT and 
its downstream target Snail both are strongly inhibited by simvastatin and SVA. While 
p38 is often associated with cell migration and has decreased activation under SVA and 
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AM1 treatment (Fig. 4.5A), its inactivation by statins does not correlate with migratory 
activity (Fig. 4.3C). Furthermore, as shown in Figure 4.5D, p38 inhibition has no impact 
on C-81 motility. In comparison, ErbB-2 inhibition impedes migration by about 40% and 
AKT inhibition reduces migration by over 80%. The data together indicates statin 
derivatives reduce the PCa cell migratory ability and tumorigenicity, in part, through 
inhibition of the AKT pathway. 
In summary, our study uses the clinically relevant LNCaP C-81 cell line model to 
demonstrate the novel compound SVA is a potent antagonist of CR PCa tumorigenicity 
and functions to suppress tumor phenotype through concurrent inhibition of AR and AKT 
pathways. As depicted in Figure 4.7, statin derivatives suppress tumor progression in 
two ways: first, these compounds inhibit androgen biosynthesis from cholesterol in CR 
PCa cells which obtain intracrine regulation [11]. In addition, the lack of cholesterol 
reduces the cell membrane’s integrity which is necessary for ErbB-2 and downstream 
AKT function. It is also possible the statins physically interact with and suppress AKT. 
While both AR and AKT signaling contribute to PCa cell tumor phenotype including 
proliferation and migration, our data indicates inhibition of the AKT pathway is the 
primary mechanism by which statin agents mediate tumor suppression. Importantly, 
aberrant AKT signaling is prevalent in a major subpopulation of advanced prostate 
tumors which endows statin derivatives with broad therapeutic potential. Moreover, statin 
derivatives are well-tolerated by patients and SVA was found to have an added effect 
when combined with docetaxel treatment (Fig. 4.6). This implies SVA can be used to 
supplement docetaxel, which possess more severe side effects, in order to improve 
patient quality of life. Future studies are required to elucidate the mechanism through 
which statin derivatives induce oxidative stress and arrest cell cycle in S phase. Further 





Figure 4.1 Structures of statin derivatives. Simvastatin, simvastatin hydroxyacid 
(SVA), 8-(3,5-dihydroxy-7-((2-(2-hydroxyethoxy)ethyl)amino)-7-oxoheptyl)-3,7-
dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate (AM1), and 8-
(3,5-dihydroxy-7-((2-(2-hydroxy)ethyl)amino)-7-oxoheptyl)-3,7-dimethyl-1,2,3,7,8,8a-





Figure 4.1 Structures of statin derivatives. Simvastatin, simvastatin hydroxyacid 
(SVA), 8-(3,5-dihydroxy-7-((2-(2-hydroxyethoxy)ethyl)amino)-7-oxoheptyl)-3,7-
dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate (AM1), and 
8-(3,5-dihydroxy-7-((2-(2-hydroxy)ethyl)amino)-7-oxoheptyl)-3,7-dimethyl-





Figure 4.2 Effects of statin derivatives on PCa cell growth. 
(A) Dosage effect of simvastatin on LNCaP C-81 cells. Cells were plated in six-well 
plates at 2 x 103 cells/cm2 in regular medium for attachment and grown for 72 hours. 
Cells were then fed with fresh medium containing 0-20 µM simvastatin with solvent 
alone for control and grown for an additional 72 hours. Cells were trypsinized and live 
cell numbers were counted by trypan blue staining. The correlative coefficient of 
dosage effect was r=0.906; p<0.05. The results presented are mean ± SE; n=2x2. 
*p<0.05.  
(B) Cell lysates from (A) were collected for immunoblot analysis of PCNA. β-actin 
protein level was used as a loading control. Similar results were observed in two sets 
of independent experiments. 
(C) Effects of statin derivatives on the growth of LNCaP C-81 cells. Under regular 
conditions, cells were plated in six-well plates at 3 x 103 cells/cm2 and maintained for 
72 hours, then treated with fresh medium containing 20 µM statin-compounds for 72 
hours. To mimic steroid-deprived (SR) conditions, cells were plated in six-well plates 
at 2 x 103 cells/cm2 and grown for 72 hours, steroid-starved for 48 hours, then fed 
with fresh SR medium with 1 nM DHT containing 20 µM statin-compounds and grown 
for 72 hours. Cells were trypsinized and live cell number was counted. Results 
presented are mean ± SE; n=3x3. *p<0.05; **p<0.001; ***p<0.0001. 
Using the same protocol as described in (C), the effect of statin derivatives on PCa 
cell growth under SR conditions was determined for (D) VCaP - 1.5 x 104 cells/cm2, 
(E) PC-3 - 2 x 103 cells/cm2, and (F) DU145 - 2 x 103 cells/cm2, (G) RWPE-1 - 1 x 104 








Figure 4.3 Effects of statin derivatives on CR PCa tumorigenicity.  
(A) Clonogenic assay on plastic wares.  LNCaP C-81 cells were plated in six-well 
plates at 2,000 cells/well. After 24 hours, attached cells were treated with respective 
compounds at 20 µM or solvent alone as control. Cells were fed on days 3, 6, and 9 
with fresh culture media containing respective statin derivatives. On day 10, 
representative photos of colony plates were taken and the number of colonies 
counted. Results presented are mean ± SE; n=3x3. **p<0.005 ***p<0.0005. 
(B) Anchorage-independent soft agar assay. LNCaP C-81 cells were plated at a 
density of 5 x 104 cells/35mm dish in 0.25% soft agarose with a base layer of 0.3% 
agarose. After 24 hours, cells in doublets or greater were marked and excluded from 
the study. Culture medium containing respective compounds at 20 µM or solvent 
alone was added every 72 hours, and after 6 weeks, colonies were stained and fixed. 
Representative images of colonies were taken and the number of colonies counted. 
Results presented are mean ± SE; n=3x3. **p<0.005 *** p<0.0001. 
(C). Cell migration transwell assay. Cell migration was assessed via Boyden 
chamber assay. 6 x 104 C-81 cells were seeded in the transwell insert of 24-well 
plates. Medium containing 20 µM of respective compounds or solvent alone for 
control were placed in the lower chamber. After 24-hour incubation, the migrated 
cells were stained and those cells remaining in the upper chamber were removed via 
cotton swab and cells which had migrated through to the lower chamber were 
counted. Representative images are shown at 40x magnification. Results presented 









Figure 4.4 Mechanism of statin-derivative suppression of CR PCa 
tumorigenicity.  
(A) Statin derivative’s inhibition of LNCaP C-81 cholesterol synthesis. Cells were 
plated in 96-well plates at 2 x 103 cells/cm per well in regular medium and allowed to 
attach over-night then fed with fresh medium containing 20 µM statin derivatives and 
grown for 72 hours. Cells were stained with Filipin III and examined via fluorescence 
microscopy. The results presented are mean ± SE; n=5x3. *p<0.05 **p<0.005 
***p<0.0005. 
(B) Effects of statin derivatives on cell membrane integrity in LNCaP C-81 cells. 
Under regular conditions, cells were plated in six-well plates at 3 x 103 cells/cm2 and 
maintained for 72 hours, then steroid-starved for 48 hours. After, cells were fed with 
fresh SR medium with 1 nM DHT containing 20 µM statin derivatives and grown for 
72 hours. Cells were trypsinized and strained with Trypan Blue dye and the ratio of 
blue to total cells counted was recorded. The results presented are mean ± SE; 
n=3x3. **p<0.005 ***p<0.0005. 
(C) Effect of SVA on AR. LNCaP C-81 cells were treated with 20 µM SVA, 10 nM 
DHT, or both for 72 hours under SR conditions. Total cell lysate proteins were 
collected for immunoblot analysis of AR and Cyclin B1 protein levels. β-actin protein 
level was used as a loading control.  Similar results were observed in two sets of 
independent experiments. 
(D) LNCaP C-81 cells were treated with 20 µM SVA, 10 nM DHT, or both for 72 
hours under SR conditions. Cells were trypsinized and live cell numbers were 
counted. The results presented are mean ± SE; n=3x3. ***p<0.0005. 
(E) Histograms of cell cycle distributions of statin-treated LNCaP C-81 cells. Cells 
were plated in T25 flasks at 5 x 103 cells/cm2 in regular medium and maintained for 
72 hours, then steroid-starved for 48 hours, followed by treatment with 20 µM of 
respective compounds in SR medium for 72 hours. Cells were harvested using 
trypsin, stained with propidium iodide, and cell-cycle was analyzed via flow 
cytometric analysis. One set of representative data is shown. Similar results were 









Figure 4.5 Molecular profiling of LNCaP C-81 signaling upon statin-derivative 
treatment under SR conditions. 
(A) Immunoblot analysis of statin-treated LNCaP C-81 cells. Cells were plated in T25 
flasks at 5 x 103 cells/cm2 in regular medium, maintained for 72 hours, then steroid 
starved for 48 hours. Cells were treated with 20 µM of respective compounds and 
grown for an additional 72 hours under SR conditions. Cells were trypsinized and 
total cell lysate proteins were collected. Total cell lysates were analyzed for 
phosphorylated ErbB-2, AKT, and p38 by site-specific phospho-Abs as well as total 
AR, cPSA, sPSA, ErbB-2, AKT, Cyclin B1, Survivin, BclXL, p53, BAX, PARP, 
Caspase 3, NOX5, Nrf2, HO-1, NFĸB, p38, and Snail protein levels. β-actin protein 
level was used as a loading control.  Similar results were observed in three sets of 
independent experiments. 
(B) Immunoblot analysis of statin-treated VCaP cells. Cells were plated in T75 flasks 
at 1.3 x 104 cells/cm2 in regular medium, maintained for 72 hours, then steroid 
starved for 48 hours. Cells were treated with 20 µM of respective compounds and 
grown for an additional 72 hours under SR conditions. Cells were trypsinized and 
total cell lysate proteins were collected. Total cell lysates were analyzed for 
phosphorylated ErbB-2 and AKT by site-specific phospho-Abs as well as total AR, 
cPSA, ErbB-2, AKT, Cyclin B1, Survivin, PARP, Caspase 3, Nrf2 and HO-1 protein 
levels. β-actin protein level was used as a loading control.  Similar results were 
observed in three sets of independent experiments. 
(C) Analysis of ROS with DCF-DA dye in statin-treated LNCaP C-81 cells. Cells were 
plated in T25 flasks at 1 x 104 cells/cm2 and maintained for 72 hours, then steroid-
starved for 48 hours, followed by treatment with 20 µM of respective compounds in 
fresh SR medium for 72 hours. Cells were then incubated with 20 µM DCF-DA for 30 
minutes before being harvested and analyzed via flow cytometry. Results presented 
are mean ± SE; n=3. *p<0.05. 
(D). Transwell assay with LNCaP C-81 cells treated with small-molecule inhibitors. 
Cell migration was assessed via Boyden chamber assay. 6 x 104 C-81 cells were 
seeded in the transwell insert of 24-well plates. Medium containing small-molecule 
inhibitors 10 µM SB202190 (p38), 1 µM AG879 (ErbB-2), or 10 µM MK2206 (AKT) 
was placed in the lower chamber. After 24-hour incubation, the migrated cells were 
fixed and stained. Cells remaining in the upper chamber were removed via cotton 
swab and cells which had migrated through to the lower chamber were counted. 










Figure 4.6 Combination treatment of LNCaP C-81 cells with statin-derivatives 
and docetaxel. Under regular conditions cells were plated in six-well plates at 2 x 
103 cells/cm2 and grown for 72 hours, then steroid-starved for 48 hours. Cells were 
then fed with fresh SR medium with 1 nM DHT containing 5 µM statin derivatives, 1 
nM docetaxel, or both and grown for 72 hours. Solvent DMSO alone was used for 
control. Cells were trypsinized and live cell numbers were counted. The results 












Figure 4.7 Proposed inhibitory mechanism of statin-derivatives on CR PCa cell 
tumorigenicity. We propose that statin derivatives suppress CR PCa tumorigenicity 
through two different mechanisms. (1) First, cholesterol is required for de novo 
androgen synthesis and subsequent intracrine activation of androgen receptor (AR) 
in CR PCa cells. Activated AR can induce ErbB-2 phosphorylation and activation as 
well as cell cycle progression in part via up-regulation of Cyclin B1. (2) In parallel, 
cholesterol is vital to the cell membrane’s integrity and formation of lipid rafts; their 
disruption destabilizes the cell membrane as well as ErbB-2 and AKT. Moreover, 
inhibition of AKT leads to induction of apoptosis through activation of pro-apoptotic 
p53 and BAX and suppression of pro-survival protein Survivin as well as Cyclin B1. 
Statin-induced AKT inhibition also leads to suppression of cell migration, in part 
mediated through Snail. Nevertheless, direct interaction between statin agents and 
ErbB-2 or AKT is possible. Thus through concurrent inhibition of both AR and AKT 
signaling pathways in addition to plasma membrane destabilization, statin derivatives 
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Metastatic castration-resistant (CR) prostate cancer (PCa) is a lethal disease for 
which no effective treatment is currently available. p66Shc is an oxidase elevated in 
patients with PCa and multiple CR PCa cell lines that promotes androgen-independent 
cell growth through generation of reactive oxygen species (ROS) We hypothesize 
p66Shc also increases the migratory activity of CR PCa cells through ROS and thus 
investigate the associated mechanism. Using the transwell assay, our study reveals that 
the level of p66Shc protein correlates with castration-resistance and cell migratory ability 
across several PCa cell lines. Furthermore, we show peroxide treatment induces 
migration of androgen-sensitive cells that express low levels of p66Shc in a dose-
dependent manner, while antioxidants inhibit migration. Moreover, stable p66Shc cDNA 
transfected subclone cells possess increased cell migration which is mitigated upon 
p66Shc shRNA transfection or expression of oxidase-deficient dominant-negative 
p66Shc W134F mutant. Protein microarray and immunoblot analyses reveal multiple 
proteins activated by p66Shc which could play a functional role in cell migration. These 
include ErbB-2, AKT, mTOR, ERK, FOXM1, PYK2, and Rac1, and their involvement in 
PCa migration was confirmed using small-molecule inhibitors. The role of Rac1 was 
further validated using cDNA transfection and, significantly, p66Shc is found to promote 
lamellipodia formation through Rac1 activation. Together, our results indicate p66Shc 
not only promotes androgen-independent cell growth in patients with metastatic CR 
PCa, but we now present evidence that p66Shc increases cell migration through ROS-
mediated activation of migration-associated proteins, notably Rac1. 
5.2 Background and Rationale 
Prostate cancer (PCa) remains the most commonly diagnosed solid tumor and 
third leading cause of cancer-related death in United States men [1,2]. Localized PCa is 
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generally not lethal and effectively treated by means of surgery or radiation therapy. It is 
not until the tumor metastasizes and spreads to vital organs that it becomes life-
threatening. While metastatic PCa is initially suppressed by androgen-deprivation 
therapy (ADT), many PCa patients relapse and develop the lethal castration-resistant 
(CR) form of the disease for which there is no effective treatment. Thus, new therapeutic 
targets must be identified. Furthermore, molecules involved in the process of PCa cell 
migration and proliferation have the potential to be promising biomarkers as well as 
remedial targets. 
p66Shc, a 66 kDa proto-oncogene Src and collagen homologue protein, exhibits 
oxidase activity and is one of three members of the Shc family of adaptor proteins, 
including p52Shc and p46Shc [3,4]. p66Shc differs from the other Shc members in 
numerous ways. For example, p66Shc protein level is regulated through post-
translational stabilization via steroids, including androgens, which play a critical role in 
the process of PCa development [4-6]. While other Shc members are ubiquitously 
expressed, p66Shc is primarily expressed in epithelial cells and has both cytosolic and 
mitochondrial localization. Structurally, p66Shc protein has an additional N-terminal CH2 
domain which contains serine phosphorylation sites that can regulate p66Shc activity 
[3,4,7]. For instance, serine 36 phosphorylation by ERK/JNK in response to stress is 
shown to induce translocation of p66Shc into the mitochondria [8, 9]. In the 
mitochondrial intermembrane space, p66Shc binds and oxidizes cytochrome C, 
uncoupling the electron transport chain and inducing production of reactive oxygen 
species (ROS) [10]. Additionally, p66Shc has been reported to induce Rac1 activation in 
mouse fibroblasts and breast cancer, though their interaction is unknown in PCa. Rac1 
is a key regulator of cell motility and can also increase ROS production via interaction 
with NOX family of NADPH oxidases [11,12]. 
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 ROS molecules are natural by-products of cellular respiration and contribute to 
essential signaling pathways; local ROS production stimulated by external growth factors 
and hormones mediates the transduction of signals from the cell membrane to the 
nucleus through the oxidation and reduction of proteins [13,14]. However, when ROS 
molecules are produced in excess, they also readily oxidize a number of cellular targets 
causing DNA, lipid, and protein damage, which facilitate various mutations and cancer 
development [15]. Furthermore, ROS is known to regulate processes like angiogenesis, 
cell adhesion, proliferation, and migration, all of which are critical to cancer metastasis 
[16-19]. Results of several studies have indicated oxidation of protein tyrosine 
phosphatases mediated by increased cellular levels of ROS can induce cell migration in 
mouse fibroblasts and more recently in human PCa cells [7,20,21]. 
 Recent studies reveal p66Shc protein levels are increased in prostate, 
thyroid, ovarian, and colon adenocarcinomas in comparison with corresponding non-
cancerous cells [6,22-24]. The level of p66Shc protein is also greater in multiple 
androgen-independent (AI) PCa cell lines which correspond with advanced metastatic 
CR PCa. For example, in the LNCaP PCa cell line, androgen-sensitive (AS) LNCaP cells 
(LNCaP-AS/C-33) possess relatively low levels of p66Shc protein [25,26]. In contrast, as 
LNCaP cells progress to androgen-independence, meaning they maintain a similar 
growth rate regardless of the presence of external androgens (LNCaP-AI/C-81), the cells 
have much higher levels of p66Shc protein on and exhibit many biochemical properties 
seen in clinical CR PCa [25-28]. These same phenomena are also observed in human 
MDA-PCa2b PCa cells, which become AI upon passage and possess increased levels 
of p66Shc; demonstrating the PCa progression in vitro correlates with an increase of 
p66Shc protein level [25,29-30]. Furthermore, p66Shc induces AI PCa cell growth, at 
least in part, by increasing cellular levels of ROS [7,25,31]. The current study is the first 
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to report p66Shc also mediates PCa cell migration, a vital process for tumor metastasis, 
and we further elucidate its signaling mechanism. Our ultimate goal is to understand the 
mechanism of PCa progression to metastatic CR PCa in order to identify novel 
biomarkers and therapeutic targets to aid the development of effective treatment options 
for this lethal disease. 
5.3 Results 
5.3.A p66Shc Protein Level Correlates with the CR Phenotype and PCa Cell 
Migration 
We initially analyzed p66Shc protein levels in primary PCa archival specimens to 
determine its association with the disease. Immunohistochemical staining was 
performed using 33 specimens in which each specimen contains both benign and 
cancerous tissues. As shown in Figure 5.1A, p66Shc protein level was found to be 
elevated in PCa adenocarcinoma with a score of 3.07 ± 0.41 when compared directly to 
benign regions with a score of 1.21 ± 0.26. Statistical analysis determined p66Shc 
protein level was significantly elevated in PCa compared to benign tissues with p < 
0.0005. 
 We then examined p66Shc protein level across multiple PCa cell lines via 
immunoblot analysis as well as their migratory potential using the Boyden Chamber 
transwell assay. As shown in Figure 5.1B, AS LNCaP cells (LNCaP-AS/C-33) have 
relatively low levels of p66Shc protein and possess correspondingly low migratory 
activity when compared to AI PC-3 and DU145 cells exhibiting higher levels of p66Shc 
as well as migration. The correlation between p66Shc protein and migration was then 
investigated using two independent PCa progression cell line models including AR-
positive LNCaP and MDA PCa2b cell lines. As shown in Figures 5.1C-D, across both 
progressive PCa cell models, p66Shc protein level and migratory activity are elevated in 
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AI cells in comparison to respective AS cells. Together, the data supports the notion that 
p66Shc protein level correlates with the AI/CR phenotype as well as cell migratory 
activity. 
5.3.B p66Shc Promotes PCa Cell Migration 
To determine p66Shc’s role in PCa cell migration, the migratory activities of 
parental LNCaP-AS, vector-alone transfected (V1) cells, and stable p66Shc cDNA-
transfected S32 and S36  subclones were investigated. As shown in Figure 5.2A, an 
increase in p66Shc protein resulted in increased migratory activity. A reversal 
experiment was then conducted in which stable p66Shc cDNA-transfected subclones 
were transiently transfected with p66Shc shRNA for analysis. For this set of 
experiments, to diminish the possible effects of variation between stable subclones, 
three individual p66Shc-stable subclones (S31, S32, and S36) were combined in equal 
number prior to shRNA transfection. As shown in Figure 5.2B, while mixed subclones 
exhibited elevated migratory activity, upon shRNA transfection both p66Shc protein 
levels and cell migration were decreased in a dose-dependent manner. Moreover, 
LNCaP-AI (C-81) cells, which possess relatively high levels of p66Shc protein as well as 
migratory activity (Fig. 5.1C), were transiently transfected with increasing amounts of 
p66Shc shRNA and then analyzed via western blot and transwell assays. As exhibited in 
Figure 5.2C, upon shRNA transfection both p66Shc protein levels and cell migratory 
activity decreased in a dose-dependent manner. The data taken together shows p66Shc 
protein level is associated with cell migratory activity and thus indicates p66Shc can 
directly regulate PCa cell migration. 
5.3.C p66Shc Promotes PCa Cell Migration via Increasing ROS Production 
p66Shc is an authentic oxidase and promotes ROS generation, at least in part, 
via oxidation of cytochrome C in the mitochondria. Moreover, p66Shc-mediated ROS 
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production induces PCa cell proliferation [31]. To determine whether p66Shc also 
promotes cell migration through ROS production, we first investigated the effects of ROS 
on PCa migration. We examined the effect of ROS on cell migration via transwell assay 
utilizing LNCaP-AS and MDA-AS cells which possess low migratory potential (Fig. 5.1C 
& 5.1D). As shown in Figure 5.3A, hydrogen peroxide treatment increased cell migration 
over 24 hours in a dose-dependent manner with 10µM having the optimal effect on both 
cell lines. To further investigate the effect of ROS on cell migration, a competitive 
inhibition transwell experiment conducted on the same cell lines using 10µM hydrogen 
peroxide, 10mM antioxidant N-acetylcysteine (NAC), or combined treatments. While 
hydrogen peroxide treatment significantly increased cell migration, Figure 5.3B 
demonstrate its enhanced effect is mitigated by combination treatment with NAC. NAC 
alone also reduces the basal migratory activity of both cell lines.  
ROS can directly increase cell migration, therefore we determined whether 
p66Shc promotes cell migration via ROS production. We conducted 24-hour transwell 
assays using p66Shc stable subclones, i.e., S31, S32 and S36, and the corresponding 
vector-alone control cells were treated with 10mM NAC (Fig. 5.3C). NAC treatment 
completely mitigated the elevated migratory activities of the subclones, indicating ROS 
generation is a key mechanism of p66Shc-induced migration. To further explore 
p66Shc’s reliance on ROS to promote cell migration, LNCaP-AI cells were transiently 
transfected with the redox-deficient DN mutant p66Shc W134F cDNA [25,31], and cell 
migration was then analyzed. This p66Shc W134F mutant has been demonstrated to 
reduce overall cellular ROS levels in PCa cells [7,31]. As shown in Figure 5.3D, upon 
transfection, LNCaP-AI cell migration decreased in a dose-dependent manner. The 
migration assay was again conducted using an equally mixed population of p66Shc 
cDNA-transfected stable subclones and the corresponding vector-alone control. Figure 
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5.3E shows that upon transfection with the redox-deficient DN p66Shc W134F cDNA, 
the elevated migration by WT cDNA in the mixed subclone population was mitigated in a 
dose-dependent manner. Collectively, the data clearly shows that p66Shc promotes PCa 
migration via its ROS-production mechanism. 
5.3.D Identification of p66Shc Down-Stream Targets and Signaling Profile 
p66Shc plays a role in regulating PCa cell migration, thus to elucidate its 
mechanism of action, we analyzed its downstream signaling. To investigate changes in 
overall protein phosphorylation signaling initiated by p66Shc expression, we prepared 
whole cell lysates from an equally mixed population of p66Shc cDNA-transfected 
subclones (S31, S32, and S36) as well as V1 control cells and analyzed the molecular 
profile via a KinexTM Antibody Microarray KAM900-P performed by the company. As 
shown in Figure 5.4A in the format of a percent change-from-control (%CFC) heat-map, 
a number of proteins had elevated activation through phosphorylation in the p66Shc 
cDNA-transfected subclones compared to vector-transfected control cells. Interestingly, 
the phosphatase PTEN, which plays a critical role in advanced CR PCa progression and 
is responsible for inactivation of some of these proteins, was found to be down-regulated 
in the subclones. Of the potential downstream-targets, we chose ErbB-2, AKT, mTOR, 
ERK, and PYK2 for further validation via western blot due to their association with PCa 
cell migration [38-43]. We also examined ROS-sensitive FOXM1 and its downstream 
target CDC25B, as well as Rac1 which are redox-sensitive and associated with 
migration [41,43-44]. We first performed immunoblot analysis to validate key molecules 
in V1 and mixed cell lysates used in the array analysis (Figure 5.4B) as well as individual 
subclone cell lysates (Figure 5.4C) to examine possible individual variation. We also 
analyzed the level of cellular prostatic acid phosphatase, cPAcP, because it is redox-
sensitive [7] and shown to function as a prostate-specific tumor-suppressor-gene in part 
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by inactivating ErbB-2 [28,32,35]; thus its decreased expression is associated with PCa 
tumorigenicity and clinical progression. Significantly, as shown in Figure 5.4B-C, cPAcP 
protein level was down-regulated in p66Shc-subclones. Consequently, protein tyrosine 
kinase ErbB-2 and its down-stream targets AKT/mTOR, ERK, PYK2, and Rac1 were 
shown to have increased activity in the subclones compared to V1 cells [29-30,45]. The 
total protein level of FOXM1, which is regulated by AKT and ERK [46], was also elevated 
in subclones along with its downstream target CDC25B (Fig. 5.4B-C). Additionally, cell 
proliferation protein Cyclin B1 was also elevated in the subclones. Thus, the array 
analysis data is validated by western blotting and together the data clearly reveals 
migration-associated downstream targets of p66Shc. 
5.3.E p66Shc Regulates Migration-Associated Proteins via ROS 
To further validate down-stream proteins associated with p66Shc/ROS signaling, 
LNCaP-AI cells and mixed p66Shc subclone cells were transiently transfected with 
p66Shc shRNA and whole cell lysates were analyzed by western blot. As shown in 
Figures 5.5A and 5.5B, knockdown of p66Shc has the reverse, dose-dependent effect 
on each previously identified signaling target in Figure 5.4. To determine whether 
p66Shc regulates these proteins through ROS production, LNCaP-AI and mixed 
p66Shc-subclone cells were transiently transfected with increasing amounts of DN 
p66Shc redox-deficient mutant W134F cDNA (Myc-Tag) for immunoblot analysis. As 
shown in Figures 5.5C and 5.5D, inhibition of cPAcP protein and activation of all other 
proteins were found to be dependent on p66Shc’s ability to generate ROS. The ratio of 
phosphorylated or GTP-activated protein to respective total protein was quantified using 
the NIH ImageJ software. Collectively, the data validates p66Shc signaling targets via 
rescue experiments and demonstrates the signaling mechanism’s reliance on p66Shc-
oxidase activity.  
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5.3.F Determination of Functional Molecules in p66Shc-Regulated PCa Cell 
Migration 
We determined the functional molecules that play a critical role in p66Shc-
mediated migration by treating p66Shc mixed subclone cells and V1 control cells with 
small molecule inhibitors and conducted a transwell migration assay (Fig. 5.6A). Due to 
the potentially significant impact of small molecule inhibitors on both cell proliferation and 
migration, the results were normalized to the growth inhibition in which cells’ 24-hour 
change in migration was divided by 24-hour change in growth. While inhibition of most 
functional proteins decreased the migration of p66Shc-subclones and V1 control cells to 
a similar level, inhibition of ERK and Rac1 had significantly greater impact on p66Shc 
subclone cells compared to V1 cells. In addition, as shown in Figure 5.6B, while no 
impact on cell migration was observed when cells were treated with FOXM1 inhibitor 
FDI-6 for 24 hours, pretreatments for 24 and 48 hours, i.e., for a total of 48 and 72 hours 
respectively, selectively inhibited subclone cell migration compared to V1 control cells 
(Fig. 5.6B). To determine if effects of FDI-6 on cell migration is entirely due to cell growth 
effect, a similar experiment was conducted measuring the FDI-6’s effect on cell growth 
over 24, 48, and 72 hours. The results showed that the inhibitory effect of FDI-6 on 
migration is greater than cell proliferation, thus showing FOXM1 contributes to PCa cell 
migration (Fig 5.6B). 
We then validated the results via a molecular approach. We focused our efforts on 
determining the role of Rac1 in the mechanism of migration because its inhibition 
resulted in the greatest impact on the migratory activity of subclones compared to V1 
control cells (Figure 5.6A). V1 control and mixed p66Shc subclones were transiently 
transfected with either vector-alone or HA-tagged dominant negative (DN) Rac1 T17N 
cDNA and a 24-hour transwell migration assay was then conducted. As shown in Figure 
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5.6C, while both transfected V1 and subclone cells had significantly reduced migration, 
subclone cells’ migration was reduced by 67% compared to only 33% of V1 cells. 
Conversely, parental LNCaP-AS (C-33) cells were transiently transfected with either 
vector-alone or HA-tagged constitutively active (CA) Rac1 G12V cDNA followed by a 24-
hour transwell migration assay. LNCaP-AS cells transfected with CA Rac1 G12V 
possessed significantly increased migration compared to the vector alone-transfected 
cells. Western blot analysis of HA-tag was conducted to ensure cDNA transfection. 
Taken together, the data clearly shows all identified p66Shc-downstream proteins 
participate in regulating cell migration signaling. Furthermore, cDNA transfection 
experiments demonstrate Rac1 activation is critical to the mechanism of p66Shc-
mediated migration. 
5.3.G p66Shc Promotes Lamellipodia Formation via Rac1 Activation 
Rac1 is a well-established regulator of lamellipodia formation, which is essential 
to cell motility [38,47]. Rac1 activation mediates p66Shc-induced migration, therefore we 
investigated the effect of p66Shc on lamellipodia formation. Initially, LNCaP-AS and –AI 
as well as V1 control and mixed p66Shc-cDNA transfected subclone cells were 
immunocytochemically stained with rhodamine phalloidin to visualize F-actin, which is 
enriched in the lamellipodia, and cells were observed using confocal microscopy (Fig. 
5.7A). The ratio of lamellipodia to total cell area was semi-quantified using NIH ImageJ 
software. Figure 5.7A shows that in the LNCaP progression model, as cells progressed 
from AS to AI, there is an observed approximately 50% increase in lamellipodia size 
which correlates with p66Shc protein level and cell migration (Fig. 5.1C). Additionally, 
p66Shc cDNA-transfected subclones possess about 50% larger lamellipodia compared 
to V1 control cells (Fig. 5.7A), which correlates with observed migration (Fig. 5.2B). The 
data together demonstrates that p66Shc expression promotes lamellipodia formation.  
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To validate whether p66Shc-induced lamellipodia formation is mediated through Rac1, 
V1 and p66Shc cDNA-transfected stable subclones were transiently transfected with DN 
Rac1 T17N cDNA. As shown in Figure 5.7B, cells were then stained with rhodamine 
phallodin to visualize F-actin and with anti-HA-Tag to identify transfected cells. Upon DN 
Rac1 T17N cDNA transfection, the lamellipodia area of both V1 and p66Shc-
overexpressing subclones was reduced by about 17% and 33%, respectively, thus a 
greater effect was observed in the p66Shc subclones. The combined data demonstrate 
p66Shc promotes lamellipodia formation in PCa cells through activation of Rac1, which 
increases their migratory activity. 
5.4 Discussion 
PCa is not life-threating until it has metastasized to vital organs. Moreover, AS 
PCa is effectively treated by ADT, while CR PCa is a lethal disease with limited 
therapeutic options. Thus, to identify novel therapeutic targets for the treatment of 
metastatic CR PCa, we investigate the functional molecules that regulate CR PCa cell 
migration. The p66Shc protein has been demonstrated to promote AI proliferation of 
PCa cells through generation of ROS and its protein level correlates with acquisition of 
the CR phenotype of PCa cell lines [6,7,25,31]. Additionally, it is proposed that ROS can 
promote motility of PCa cells, suggesting p66Shc has the potential to regulate PCa cell 
migratory activity during metastasis [16-19]. In this study, p66Shc protein levels were 
found to be elevated in prostate adenocarcinoma tissue compared to the matched 
benign tissue (Fig. 5.1A). p66Shc protein level also correlates with androgen-
independence and migratory activity in PCa cells, both in AR-null PC-3 and DU145 cell 
lines as well as both AR-positive progression model cell lines (Fig. 5.1B-D) [48,49]. This 
data reinforces the role of p66Shc in the development of androgen-independence of 
PCa cells and suggests it promotes the acquisition of aggressive migratory phenotype. 
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Further analyses demonstrates that p66Shc can regulate PCa cell migratory 
ability. While p66Shc cDNA transfection of low migratory-potential LNCaP-AS cells 
results in significantly enhanced migration, knockdown of p66Shc in high migratory-
potential LN-AI cells with p66Shc shRNA significantly decreases cell migration in a dose-
dependent manner (Fig. 5.2A-B). Moreover, the elevated migratory activity of p66Shc 
subclones was reduced in a dose-dependent manner upon p66Shc shRNA transfection 
(Fig. 5.2C). Together, the data demonstrates p66Shc has a key regulatory role in PCa 
migration. 
We next determined the mechanism through which p66Shc regulates the 
migratory activity of PCa cells. p66Shc has been demonstrated to promote PCa growth 
via ROS generation, therefore the effect of ROS on AS PCa cell migration was first 
investigated [25]. Figure 5.3A-B shows hydrogen peroxide can promote the migratory 
activity of LNCaP-AS and MDA-AS cell lines in a dose-dependent manner, which is 
mitigated upon antioxidant NAC treatment. To validate that p66Shc promotes PCa 
migration through its ability to induce ROS generation, the effect of NAC on the 
migration of p66Shc subclone cells was investigated. NAC can reduce intracellular ROS 
levels of p66Shc subclones [31], and upon NAC treatment, increased migratory activity 
of subclones was fully mitigated (Fig. 5.3C). Further, upon transfection with redox-
deficient DN p66Shc W134F cDNA, both LNCaP-AI and p66Shc subclone cell migration 
is reduced in a dose-dependent manner (Fig. 5.3D-E). Transfection of p66Shc W134F 
cDNA has previously been shown to reduce intracellular levels of ROS [7,31]. Together 
the data demonstrates the mechanism of p66Shc-induced PCa migration is reliant on 
p66Shc’s oxidase activity and generation of ROS. 
To identify the functional proteins involved in p66Shc-mediated migration, a 
global protein microarray was used to initially identify potential down-stream targets of 
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p66hc (Fig. 5.4A). The proteins chosen for further validation by immunoblot analysis are 
based on the findings of previous studies as well as their known association with cell 
migration. Briefly, p66Shc has been demonstrated to promote phosphorylation and 
activation of ErbB-2 at Y1221/2 through oxidation/inactivation of cPAcP, a phospho-
protein tyrosine phosphatase [7,28-29,35]. This allows for activation of ErbB-2 
downstream targets ERK and AKT/mTOR kinases by phosphorylation [7,25].  Though 
microarray data revealed both FAK and PYK2 adhesion proteins possessed increased 
activation in subclones, FAK has been shown to be the dominate adhesion molecule in 
prostate fibroblasts while PYK2 is the dominate protein in CR PCa adenocarcinoma; 
thus PYK2 was chosen for further study [30]. Moreover, while not included in the 
microarray, FOXM1 and its down-stream target CDC25B are up-regulated by ERK and 
AKT and shown to promote the metastatic phenotype in multiple carcinomas, though 
little is known of its role in PCa [46]. Additionally, Rac1 is a well-established regulator of 
cell migration and lamellipodia formation. Rac1 has been shown to be regulated by 
p66Shc in mouse embryonic fibroblasts as well as esophageal and breast carcinomas, 
however their interaction has not been studied in PCa [11,50,51]. Importantly, all of 
these proteins are confirmed to be activated by p66Shc in Figures 5.4B and C. To 
further validate p66Shc-regulation of each protein of interest, immunoblot analysis was 
conducted on LNCaP-AI and mixed subclone cells transfected with p66Shc shRNA and 
p66Shc oxidase-deficient mutant DN W134F cDNA. Figures 5.5A-D show all proteins 
were confirmed to be down-regulated in a dose dependent manner upon p66Shc knock-
down and transfection of DN p66Shc W134F cDNA, with the exception of PAcP, a 
negative growth regulator [35], which was increased as expected. Thus, this data 
demonstrates these molecules are activated by p66Shc-mediated ROS generation. 
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The involvement of each protein in PCa cell migration was then investigated to 
determine its functional role in p66Shc-induced migration. As shown in Figure 5.6A and 
B, small molecule inhibitors were initially used to screen for the effects of each protein 
on the migration of p66Shc subclones and results were normalized to their respective 
24-hour growth inhibition. While the FOXM1 inhibitor FDI-6 did not significantly inhibit 
migration over 24 hours, 48-hour pretreatment (72 hours total treatment) with small-
molecule inhibitor FDI-6 significantly reduced the migration, but not growth, of subclones 
compared to V1 control cells. Moreover, p66Shc subclones are more sensitive to ERK 
and Rac1 inhibition compared to V1 cells, possibly because the cells are now reliant on 
these signaling pathways due to increased p66Shc levels. Overall, inhibition of Rac1 has 
the greatest impact on migration, thus, Rac1 was chosen for further validation through 
cDNA transfection. Shown in Figure 5.6C, upon transfection of V1 and p66Shc 
subclones cells with DN Rac1 T17N cDNA, cell migration was inhibited by about 30% 
and 70%, respectively, demonstrating p66Shc is reliant on Rac1 activation to induce 
PCa migration. Conversely, upon transfection of parental LNCaP-AS cells with 
constitutively-active Rac1 G12V cDNA, cell migration was increased by about 45%. 
Notably, there was no significant difference in migration between control V1 and parental 
LNCaP-AS cells, demonstrating transfection with vector alone has no phenotypic effect. 
Together, the data reveals while p66Shc-induced activation of multiple proteins 
contribute to increased PCa cell migration, Rac1 activation plays a mechanistic role.  
It is established that the primary mechanism by which Rac1 promotes cell 
migration is through facilitating the formation of lamellipodia [11]. Therefore, lamellipodia 
formation was investigated and observed via confocal microscopy where F-actin, which 
is enriched in cell lamellipodia, was stained with rhodamine phalloidin. As shown in 
Figure 5.7A, the relative size of lamellipodia compared to total cell area increased as 
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LNCaP cells progressed from AS to AI, correlating with observed increase in p66Shc 
protein level and migration (Fig. 5.1C). Similarly, the size of lamellipodia was increased 
in p66Shc subclones compared to V1 cells, again correlating with an increase in cell 
migration (Fig. 5.2B). Furthermore, upon transfection of p66Shc subclones with DN 
Rac1 T17N cDNA, lamellipodia area was reduced by twice as much as V1 cells (Fig. 
5.7B), which closely correlates with observed decrease in migration (Fig. 5.6C). 
Collectively, the data demonstrates Rac1 activation is vital to the mechanism of p66Shc-
indueced lamellipodia formation and migration. 
In summary, our results show that p66Shc promotes PCa metastatic progression 
through ROS-dependent induction of cell migration. As Figure 5.8 summarizes, p66Shc 
can be translocated to the mitochondria where it oxidizes cytochrome C, decoupling the 
electron transport chain and generating ROS. The increase in cellular ROS leads to 
inactivation of cPAcP, preventing de-phosphorylation of ErbB-2 and promoting activation 
of ErbB-2 downstream migration-associated proteins including: ERK, AKT, mTOR, 
FOXM1, PYK2, and Rac1. Nevertheless, there are additional mechanisms through 
which p66Shc may activate Rac1, independent of ErbB-2. Interestingly, p66Shc has 
been reported to activate Rac1 through cytosolic interaction with Son of Sevenless 1 
(SOS1) protein [52]. ROS has also been shown to directly mediate Rac1 GDP-GTP 
nucleotide exchange and thus is another possible mechanism of p66Shc-mediated Rac1 
induction [53]. The exact mechanism of p66Shc-Rac1 interaction regulating in PCa 
migration requires further investigation. We will also elucidate the role and mechanism of 
several other proteins in p66Shc-mediated PCa metastasis and validate with clinical 
relevance. 
To conclude, this work highlights p66Shc’s potential as a PCa biomarker for 
identification of aggressive metastatic phenotype as well as tumor progression towards 
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androgen-independence. Importantly, because p66Shc possesses enzymatic activity, it 
has the potential to be a potent therapeutic target for suppression of tumor proliferation 
and migration. Moreover, combined inhibition of p66Shc and its downstream target Rac1 
may provide an effective method to combat metastatic CR PCa. Understanding 
p66Shc’s involvement in advanced PCa progression will help determine its potential as a 
therapeutic target, and elucidating its mechanism of intracellular signaling will enable us 











Fig. 5.1 p66Shc protein level correlates with the CR phenotype and PCa cell 
migration. (A) Immunohistochemical staining of malignant and matched benign 
human prostate tissues with anti-p66Shc Ab, n=33. (B,C,D) Immunoblot staining for 
Shc and loading control β-actin using androgen-sensitive LNCaP (LN-AS/C-33), 
PC3, DU145 (B), androgen-sensitive (AS) C-33 and androgen-independent (AI) C-81 
LNCaP (C) and AS and AI MDA-PCa2b (D) cell lines. The transwell assay was 
conducted in which cells were seeded in 24-well plate transwell inserts (5x104 cells 
per well) and allowed to migrate for 24 hours. Migrated cells were fixed and stained 
before counting. Images at 40x magnification. Results presented are mean ± SE; 






Fig. 5.2 p66Shc promotes PCa cell migration. (A) Immunoblot staining for Shc and 
loading control β-actin using LNCaP-AS C-33 cells transfected with vector-alone (V1) 
or p66Shc cDNA to generate stable subclones S32 and S36. The transwell assay 
was conducted in which cells were seeded in 24-well plate transwell inserts (5x104 
cells per well) and allowed to migrate for 24 hours. Migrated cells were fixed with 
methanol and stained with crystal violent before counting. Images at 40x 
magnification. (B) V1 or equally mixed population of stable S31, S32, and S36 
subclones transiently transfected with 0-6µg p66Shc shRNA or vector alone. 
Immunoblot staining and transwell assays were conducted as described in (A). (C) AI 
LNCaP C-81 cells transiently transfected with 0-6µg p66Shc shRNA or vector alone. 
Immunoblot staining and transwell assays were conducted as described in (A). 











Fig. 5.3 p66Shc promotes PCa cell migration via ROS. (A) Transwell assay in 
which androgen-sensitive (AS) LNCaP C-33 or MDA-PCa2b cells were seeded in 24-
well plate transwell inserts (5x104 cells per well), treated with 0-20µM hydrogen 
peroxide in the lower chamber, and allowed to migrate for 24 hours. Migrated cells 
were fixed and stained before counting. (B) Transwell assay as described in (A) in 
which AS LNCaP C-33 or MDA-PCa2b cells were treated with 10µM hydrogen 
peroxide, 10mM NAC, or both. (C) Transwell assay as described in (A) using V1 or 
stable subclones treated with or without 10mM NAC in the lower chamber of the 
transwell (D,E) Androgen-independent (AI) LNCaP C-81 (D) or V1 and equally mixed 
population of stable S31, S32, and S36 subclone cells (E) were transiently 
transfected with 0-6µg of dominate-negative redox-deficient p66Shc W134F cDNA or 
vector alone. Transwell assays were conducted as described in (A). Results 




Fig. 5.4 Identification of p66Shc down-stream targets by molecular profile. (A) 
Total cell lysates of V1 or equally mixed population of stable S31, S32, and S36 
subclones analyzed via Kinexus KAM-900P protein microarray. Results presented as 
percent change from control (%CFC) in which red represents an increase and green 
a decrease in protein levels. (B,C) Immunoblot analysis of total cell lysates from V1 
or equally mixed population of stable S31, S32, and S36 subclones used in the 
protein microarray (B) or V1 and individual stable S31, S32, and S36 subclones (C). 
Total and phosphorylated or GTP-activated proteins associated with migration were 






Fig. 5.5 p66Shc regulates migration-associated proteins via ROS. (A,B) 
Immunoblot analysis of androgen-independent (AI) LNCaP C-81 (A) or V1 and 
equally mixed population of stable p66Shc subclones (B) transiently transfected with 
0-6µg p66Shc shRNA or vector alone. Total cell lysates were analyzed for previously 
identified total and phosphorylated or GTP-activated proteins associated with 
migration. Ratio of phosphorylated or GTP to total protein was quantified using 
ImageJ software. β-actin was used as a loading control. (C,D) Immunoblot analysis 
of AI LNCaP C-81 (C) or V1 and equally mixed population of stable subclones (D) 
transiently transfected with 0-6µg dominate-negative redox-deficient p66Shc W134F 












Fig. 5.6 Determination of functional molecules in p66Shc-regulated PCa cell 
migration. (A) Transwell assay using V1 or equally mixed population of stable 
subclones treated with small-molecule inhibitors (at IC50 in LNCaP cells) in the lower 
chamber of the transwell for functional migration-associated proteins previously 
identified. Cells were seeded in 24-well plate transwell inserts (5x104 cells per well) 
and allowed to migrate for 24 hrs. Migrated cells were fixed and stained before 
counting. Cell migration is normalized to small-molecule 24 hour growth inhibition. 
(B) Transwell assay using V1 or equally mixed population of stable subclones treated 
with 5µM FOXM1 inhibitor FDI-6 (IC50 in LNCaP cells). Cells were treated with FDI-6 
in the lower chamber during the 24 hour transwell or with additional 24 or 48 hour 
pre-treatment (For a total of 24, 48, and 72 hours of FDI-6 treatment). FDI-6 effect on 
cell growth of V1 or equally mixed population of stable subclone cells was 
determined. Cells were seeded at 3x103 cells/cm2 and allowed to attach for three 
days before treated with 5µM FDI-6 for 24, 48, and 72 hrs. Cells were trypsinized 
and live cell number was counted. (C) V1 or equally mixed population of stable 
subclones were transiently transfected with HA-Tagged dominate-negative Rac1 
T17N cDNA or vector alone. AS LNCaP C-33 cells were transiently transfected HA-
Tagged constitutively-active Rac1 G12V cDNA or vector alone. Transwell assay was 
conducted as described in (A). Successful transfection was determined via 
immunoblot of whole cell lysates for HA-Tag. β-actin was used as a loading control. 











Fig. 5.7 p66Shc promotes lamellipodia formation via Rac1 activation. (A) 
Androgen-sensitive (AS) C-33 and androgen-independent (AI) C-81 LNCaP, V1, and 
equally mixed population p66Shc subclone cells were stained with F-actin binding 
rhodamine phalloidin (Red) to visualize lamellipodia and DAPI (Blue) to detect nuclei. 
The ratio of lamellipodia to total cell area of 20 randomly selected cells was 
quantified. (B) V1 and equally mixed population subclone cells were transfected with 
HA-Tagged DN Rac1 cDNA and stained with F-actin binding rhodamine phalloidin 
(Red) to visualize lamellipodia, DAPI (Blue) to visualize nuclei, or anti-HA-tag (Green) 
to visualize dominant-negative Rac1 cDNA transfected cells. The ratio of lamellipodia 
to total cell area of 20 randomly selected cells was quantified. Results presented are 





Fig. 5.8 Proposed mechanism of p66Shc-regulated PCa cell migration. Upon 
elevation of protein level, p66Shc translocates to the mitochondria where it binds and 
oxidizes cytochrome c, decoupling the electron transport chain, and generating ROS. 
Increased cellular ROS oxidizes cellular prostatic acid phosphatase (cPAcP), 
preventing it from dephosphorylating ErbB-2. Phosphorylated ErbB-2 then activates 
downstream targets PI3K/AKT/mTOR, ERK, FOXM1, PYK2, and Rac1, all of which 
contribute to PCa cell migration. p66Shc may also activate Rac1 via SOS1 in the 
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 The overall goal of my work is to advance therapeutic strategies for 
treatment of CR PCa, a currently incurable, lethal disease. Importantly, due to our 
laboratory’s access to multiple progressive PCa cell line models, we have a unique 
opportunity to investigate aspects of the disease in a clinically relevant system. In my 
first body of work, I investigate a panel of novel imidazopyridine derivatives as potential 
therapeutic agents for CR PCa and investigate their mechanism of inhibition. This group 
of compounds was selected for their known ability to suppress AKT activation, a primary 
downstream target of AR which promotes androgen independence as well as aggressive 
metastatic phenotype. The template compound HIMP was altered through the addition of 
various of substituent groups in hopes of synthesizing a compound effective at duel 
inhibition of AKT and AR pathways. The simultaneous inhibition of both pathways is 
key due to their ability to cross-activate and compensate for suppression of the other. 
Initial screening of the compounds’ ability to suppress LNCaP-AI (C-81) cell growth in 
regular and steroid-reduced conditions revealed compounds M-MeI and EtOP maintain 
their inhibitory activity, regardless of the presence of androgens. Further screening of 
these compounds on a panel of castration-resistant cell lines as well as immortalized 
benign prostate epithelial cells exposed M-MeI’s selective inhibition of CR PCa. Further 
tumor phenotypic assays confirmed M-MeI as the comparatively superior tumor 
suppressor and immunoblot analysis show it is a potent inhibitor of both AR and AKT 
activation. Additional cell-cycle analysis show M-MeI arrests the cell cycle in G2 phase 
as well as strongly induces apoptosis. However, the precise mechanism of its inhibitory 
activity remains unclear. Thus, M-MeI shows promise as future therapeutic agent for 
155 
 
treatment of CR PCa due to its selective growth inhibition and duel suppression of both 
the AR and AKT pathways. 
In my second body of work, I investigate the effects of novel statin derivatives on 
CR PCa metastatic activity. While the imidazopyridines were studied for their ability to 
combat AKT-mediated androgen-independence, the use of statin derivatives aims to 
prevent de novo androgen synthesis by PCa cells, an alternative method of over-coming 
androgen ablation therapy. By preventing cholesterol synthesis, statins effectively deny 
PCa cells of precursor compounds necessary to synthesize androgens. One of the major 
draws of statins as therapeutic agents is that their side-effects on humans are well studied 
and overall exceptionally mild compared to those of other drugs used to treat CR PCa. In 
this study, template compound simvastatin is synthesized in its constitutively active form 
(SVA) and several substituents were again added to the structure in attempt to modulate 
its activity. Significantly, while simvastatin’s growth suppression of LNCaP-AI (C-81) 
cells is reduced under steroid-deprived conditions, the activities of the novel statin 
derivatives remain unaltered. Most importantly, while derivatives AM1 and AM2 
demonstrated minimal selective inhibition of PCa cell growth compared to benign 
epithelial cells, SVA was very selective for PCa growth inhibition. Additional assays for 
colony formation and cell migration revealed SVA was a more potent suppressor of PCa 
metastatic phenotype than simvastatin, while AM1 and AM2 were less effective. Further 
evaluation demonstrated SVA was a more potent suppressor of cholesterol synthesis than 
simvastatin and can induce cell membrane damage via permeabilization. Interestingly, 
while the addition of androgens can mitigate SVA inhibition of AR, its inhibition of cell 
growth remains unchanged, pointing to additional mechanisms of PCa tumor suppression 
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beyond preventing de novo androgen synthesis. I speculate this is due to SVA’s 
damaging effect on the cell membrane by preventing lipid raft formation, which anchors 
multiple proteins required for pro-tumorigenic signaling. Further immunoblot analysis 
shows SVA is a more potent inhibitor of AR, ErbB-2, AKT, and multiple pro-
proliferative proteins compared to simvastatin. Perhaps most importantly, SVA is 
demonstrated to have an added effect when combined with chemotherapeutic agent 
docetaxel. Docetaxel is sometimes used to treat end-stage CR PCa and possesses 
notoriously toxic side effects.  My hope is that novel compound SVA can be used in 
conjunction with existing therapeutic agents for CR PCa in effort to maintain anti-tumor 
effects and reduce patient toxicity. Moreover, like the imidazopyridine derivatives, SVA 
demonstrates potent duel inhibition of both AR and AKT pathways, making it a 
promising treatment compound. 
Finally, in my third body of work I step away from the investigation of novel 
therapeutic agents and instead focus on studying p66Shc, a protein previously identified 
to promote androgen-independent growth through the generation of ROS. Our goal is to 
identify proteins regulating processes critical to PCa metastasis to act as biomarkers for 
aggressive tumor phenotype and serve as novel therapeutic targets for future compounds. 
ROS has been shown to promote migratory activity in other tumor cell lines, thus we 
theorized p66Shc also promotes PCa migration in mechanism similar to its growth 
regulation. First, p66Shc protein level was demonstrated to not only correlate with PCa 
progression to androgen independence, but also the migratory activities of various PCa 
cell lines. Next, p66Shc cDNA transfection was demonstrated to increase migration of 
androgen-sensitive LNCaP cells, while shRNA transfection reduced migration of both 
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androgen-independent LNCaP cells and p66Shc over-expressing subclones. p66Shc-
mediated migration was then shown to be reliant on generation of ROS. Treatment of 
p66Shc subclones with antioxidant NAC or transfection with redox-deficient p66Shc 
mutant W134F cDNA reduced the cells’ migration and similar results were observed 
using androgen-independent LNCaP cells (C-81). The mechanism of p66Shc-induced 
migration was further explored using protein microarray and immunoblot analyses to 
identify key signaling molecules in p66Shc cDNA transfected LNCaP cells. The results 
were then verified using immunoblot analysis of LNCaP-AI (C-81) and p66Shc 
subclones transfected with shRNA in which the opposite signaling patterns were 
observed. Additional immunoblot analysis of LNCaP-AI (C-81) and p66Shc subclones 
transfected with redox-deficient p66Shc W134F cDNA demonstrated p66Shc regulation 
of down-stream signaling targets was reliant on its ability to generate ROS. Downstream 
p66Shc targets ErbB-2, AKT, mTOR, ERK, Rac1, PYK2, and FOXM1 were then 
demonstrated to contribute to PCa cell migration with Rac1 having the greatest impact. 
Rac1’s involvement in migration was further verified via cDNA transfection and 
demonstrated to mediate p66Shc-induced lamellipodia formation using F-actin staining. 
Overall, the study demonstrated for the first time that p66Shc plays a critical role in the 
process of CR PCa migration and identifies numerous proteins involved in the 
mechanism. My hope is that this work supports future efforts to generate therapeutic 
compounds for CR PCa patients and that these proteins may serve as biomarkers for early 





6.2 Future Directions 
 While the results of these studies are promising for future treatment of CR PCa, 
more work is required to apply them to a clinical setting. In the case of both 
imidazopyridine and statin derivatives, while they selectively suppress PCa 
tumorigenicity, the precise mechanism of action remains unclear. Imidazopyridines 
encompass a large class of compounds that bind and inhibit a wide variety of cellular 
targets. While M-MeI is a potent inhibitor of AR and AKT, it is uncertain whether it 
binds these proteins directly or suppresses them through inhibition of up-stream 
regulators. The reason M-MeI arrests the cell cycle at G2 phase is also obscure and 
additional analysis is necessary. Moreover, while M-MeI shows selectivity in vitro, in 
vivo experiments are required to test its toxicity, a major concern for potential clinical 
use. Furthermore, it remains unclear whether imidazopyridine derivatives would be able 
to reach the tumor in an in vivo system or be readily absorbed by tumor cells. In addition, 
the concentration of M-MeI required to observe cytotoxic effects is around 10 µM in 
steroid-reduced conditions. This concentration is likely on the upper end of clinically 
achievable levels, thus additional side-chain modification to improve the potency of M-
MeI is required for future study. Further side-chain modification may also endow M-MeI 
with additional tumor-suppressing effects. Future studies should also test combinations of 
M-MeI with other FDA-approved drugs in attempt to produce additive or synergistic 
therapeutic effects. Finally, while the imidazopyridine derivatives are effect against CR 
PCa cells, they may also be useful tools for treating other carcinomas. The AKT axis is 
commonly deregulated in most cancers, thus it is reasonable to suspect M-MeI may be 
applicable to a wide range of tumors.  
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Future work on the statin derivatives is similar to that of the imidazopyridine 
compounds. First, their mechanism of PCa inhibition requires further clarification. While 
SVA clearly reduces cellular cholesterol levels, we are uncertain whether it inhibits the 
cells’ ability to synthesize androgens de novo. Furthermore, the results indicate inhibition 
of androgen synthesis is not the driving mechanism of tumorigenicity suppression; 
instead it is likely that reduction of cellular cholesterol impedes lipid raft formation, 
which anchors proteins critical to PCa signaling. Future work on these compounds should 
investigate the effect of statin compounds on lipid rafts and how formation of these 
structures regulates AKT and AR signaling. In addition, like the imidazopyridines, it is 
uncertain what SVA is binding to in the cell. While it almost certainly binds and inhibits 
HMG-CoA reductase, it may also have a number of off-target effects including direct 
AKT or AR binding. While the toxicity of the drug is expected to be low, in vivo 
experiments are still required to demonstrate its clinical application. Importantly, SVA 
has an added effect when combined with docetaxel and may have similar properties when 
used together with other compounds. Docetaxel is also a commonly used 
chemotherapeutic agent and because SVA inhibits AKT, a widely deregulated protein in 
multiple carcinomas, it can likely be used to treat multiple cancers in addition to PCa. 
Finally, as with M-MeI, SVA can be further modified in order to increase potency and 
potentially give it additional tumor-suppressing properties. Both M-MeI and SVA show 
exceptional promise as therapeutic agents for CR PCa due to their duel suppression of 
AR and AKT as well as selective inhibition. Future investigation of their mechanism of 




While the investigation of novel therapeutic compounds is important for the 
future of PCa research, it is also necessary to continue examining the underlying 
mechanisms of PCa progression towards castration-resistance and aggressive metastatic 
phenotype. My third body of work demonstrates elevation of p66Shc protein level as a 
driving force behind CR PCa migration and identifies a number of key proteins in the 
mechanism, notably Rac1. While the mechanism in which p66Shc activates ErbB-2 and 
its downstream signaling cascade clearly revolves around oxidation and inactivation of 
cPAcP, it is not immediately known how p66Shc interacts with Rac1 in PCa. Rac1 may 
be activated by ErbB-2, ROS, or SOS1-mediated p66Shc binding. Further investigation 
of their interaction will be the subject of future studies. 
Presently, the next step in this investigation is to carryout in vivo experiments to 
determine whether p66Shc similarly induces migration in a mouse model as well as 
investigate its potential as a therapeutic target. In addition, there is currently no inhibitor 
compound available for p66Shc, thus this may also be the subject of future work. 
Moreover, inhibition of p66Shc may not be appropriate for all stages of PCa due to its 
promotion of ROS generation. Early stages of PCa typically have lower levels of ROS 
and may benefit from p66Shc-mediated ROS production, thus p66Shc may be a good 
target for these cells. However, late-stage PCa may have much higher basal levels of 
ROS, which induces cellular stress and in some cases apoptosis. Inhibition of p66Shc in 
these cells may actually aid their survival. Therefore, it is reasonable to assume 
aggressive metastatic PCa cells, which possess elevated p66Shc levels, must also have 
elevated anti-oxidant molecules to regulate ROS production and keep it at optimal 
concentrations. This is the current focus of our laboratory’s work. Targeting antioxidant 
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molecules in metastatic CR PCa has the potential to be an effective therapeutic strategy 
by impeding their ability to regulate ROS produced by elevated p66Shc levels. In 
addition, combined inhibition of p66Shc as well as some of its downstream signaling 
partners such as Rac1, ErbB-2, ERK, AKT, mTOR, and PYK2 may also be an effective 
means of treatment. Finally, while p66Shc has been identified as a critical promoter of 
aggressive metastatic phenotype and acquisition of castration-resistance, the manner 
through which it is regulated in PCa cells is little understood. Only a small number of 
transcription factors have been verified to bind p66Shc’s promoter and while AR protects 
p66Shc from ubiquitination and degradation, the mechanism is unclear. Most 
importantly, the mechanism governing p66Shc translocation into the mitochondria is 
currently obscure. While ERK/JNK phosphorylation of p66Shc at S36 has been 
demonstrated to induce mitochondrial translocation, this process is associated with 
p66Shc-induced apoptosis and not cell growth. Furthermore, the precise mechanism 
through which p66Shc moves across mitochondrial membrane is a mystery. Thus, a 
significant amount of work is still required to fully understand how p66Shc functions in 
PCa and in what manner its signaling mechanism can be exploited for future therapeutic 
strategies. 
